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ABSTRACT
CLASSIFICATION OF CLINICAL OUTCOMES USING HIGH-THROUGHPUT
AND CLINICAL INFORMATICS
Alexander C. Cambon
November 19, 2014
It is widely recognized that many cancer therapies are effective only for a subset of patients.
However clinical studies are most often powered to detect an overall treatment effect. To address
this issue, classification methods are increasingly being used to predict a subset of patients which
respond differently to treatment. This study begins with a brief history of classification methods
with an emphasis on applications involving melanoma. Nonparametric methods suitable for
predicting subsets of patients responding differently to treatment are then reviewed. Each method
has different ways of incorporating continuous, categorical, clinical and high-throughput
covariates. For nonparametric and parametric methods, distance measures specific to the method
are used to make classification decisions. Approaches are outlined which employ these distances
to measure treatment interactions and predict patients more sensitive to treatment. Simulations are
also carried out to examine empirical power of some of these classification methods in an
adaptive signature design. Results were compared with logistic regression models. It was found
that parametric and nonparametric methods performed reasonably well. Relative performance of
the methods depends on the simulation scenario. Finally a method was developed to evaluate
power and sample size needed for an adaptive signature design in order to predict the subset of
patients sensitive to treatment. It is hoped that this study will stimulate more development of
nonparametric and parametric methods to predict subsets of patients responding differently to
treatment.
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Key Words: classification; machine learning; dimension reduction; interaction; melanoma;
clinical study.
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NONPARAMETRIC CLASSIFICATION METHODS

1. Introduction
Overview of Nonparametric Classification Methods
Classification is a subset of what Hastie, Tibshirani, & Friedman (2009 [75]) term the
statistical learning field, and what Bishop (2006 [10]) refers to as pattern recognition or machine
learning. Statistical learning can further be divided into two categories, supervised learning and
unsupervised learning, as shown in Figure 1. “It is called ‘supervised’ because of the presence of
the outcome variable to guide the learning process. In the unsupervised learning problem, we
observe only the features and have no measurements of the outcome.” (Hastie et al., 2009 [75]).
In language often used in machine learning or pattern recognition, supervised learning
methods have both inputs and outputs. Pattern recognition uses the term features for inputs. In the
statistical field, the outputs are referred to as the outcome, response, or dependent variables, and
the inputs are covariates, explanatory variables, or independent variables. These covariates can be
high dimensional, such as genomic data, or low dimensional, such as age, gender, ethnicity,
tumor thickness, or presence of ulceration.
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Figure 1: Flowchart showing subdivisions of statistical learning methods.

As seen in Figure 1, supervised learning can then be further subdivided into classification
(modeling and predicting of categorical outcomes), and regression (modeling and prediction of
continuous outcome variables). In classification, the categorical outcomes are the class labels
which the classification method is predicting. However regression methods are also often
included as a step in the classification process.

2

Figure 2: Flowchart of Classification Process. Steps shown separately such as dimension reduction and
model building may be part of the same step.

Figure 2 shows a high level flowchart of the classification process. Model building is done on
the training set, and prediction error assessed on the validation set. To prevent over fitting during
model building, the training set itself is often divided up into nested training and validation steps.
Within each paired training and validation set, the training and validation portions are usually
non-overlapping.
The roots of discriminant analysis, a class of methods used to separate labeled groups of
objects using covariates, date back to well before 1936, when Mahalanobis published his work on
the “generalized distance” (1936 [111]), and Fisher published a closely related method, using the
3

same distance, to discriminate between species of iris (1936 [48]). Ensuing developments in
nonparametric classification include K Nearest Neighbors (KNN) and Kernel Density Analysis
(KDA) used for classification, both proposed by Fix & Hodges (1951 [49]).
These earlier methods were developed before the proliferation of high-throughput data
(HTD), such as genomic or proteomic data. HTD typically have thousands or more of features,
together with sample sizes on the order of 100 or less. This situation is often referred to as

p  n where p refers to the features and n refers to the sample size of subjects. The early
methods cannot handle p  n data without dimension reduction (DR) methods. Many DR
methods have been originated for HTD to address this situation. Additional classification
methods such as Random Forests (Breiman, 1999 [17]), Support Vector Machines (Boser, Buyon,
& Vapnik, 1992 [12]) and Boosting (Freund & Schapire, 1995 [56]) have built-in (embedded) DR
techniques. At the same time many of the earlier developed classification methods, when used in
conjunction with DR techniques, compare favorably to these more recently developed methods.
For example KNN outperformed Boosting and Random Forests in a comparison of methods by
Dudoit, Fridlyand, & Speed (2002 [39]) involving genomic data.
Some Early Uses of Genomic Data, Clustering, and Classification
In the late 1990’s and early 2000’s unsupervised methods were used to show that genomic
data could be used not only to identify known classes but also to identify or predict new classes.
Golub et al. (1999 [66]) developed a method involving clustering and weighted voting of
“informative” genes for cancer classification. Their results pointed in the direction of “a general
strategy for discovering and predicting cancer classes for other types of cancer, independent of
previous biological knowledge”. This method was able to discriminate between two types of
leukemia. Treatment regimens could then be targeted to the type of leukemia if it were known.
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Development of Medical and Statistical Classification Methods in Melanoma
Following closely after the work of Golub et al. (1999 [66]), Bittner et al. (2000 [11]) applied
clustering and multiple dimensional scaling (MDS) to a melanoma study and found that gene
expression patterns correlated by specific subsets of melanomas. This finding pointed toward the
possibility of classification of melanoma based on gene expression. It was only more recently that
the prognostic system for melanoma as defined by the American Joint Committee on Cancer or
AJCC (Balch et al., 2009 [5]) officially added mitotic rate to the other prognostic variables.
Although no molecular marker was included with this latest update (Duncan, 2009 [40]), the
addition of mitotic rate to the AJCC Index in 2009 was seen as evidence of “heightened interest
in the utility of molecular markers” for melanoma (Segura et al., 2010 [147]). However, although
factors such as number of metastatic nodes and tumor thickness explain “tremendous
heterogeneity of prognosis among patients with stage III melanoma” (Balch et al., 2010 [6]),
Duncan (2009 [40]) and Balch et al. (2004 [4]) pointed out that the AJCC melanoma cancer
classification system “is a tumor-node-metastasis (TNM) based clinical and histologic scheme
that segregates patients into prognostic categories that are not correlated with any specific
therapeutic response”. Duncan further stated that “integration of the genomic and clinical
pathologic schemes may provide a future classification scheme that segregates tumors by
predicted outcome and potential response to specific therapy.”
The earlier classification systems for melanoma, as in other fields, underwent an evolution.
Table 1 of the Rigel, Russak, & Friedman study (2010 [133]) showed the primary diagnosis of
melanoma was, before the 1980’s confined to gross features such as bleeding ulceration, but
progressed to use of subsurface features in the 1990’s and eventually to digital and subcellular
feature after the turn of the century. The ABCD (asymmetry, border, color, differential structure)
system was developed in the United States by Friedman, Rigel, & Kopf (1985 [61]) for selfexamination and early detection. The 7-Point Checklist was also devised in the same year in the
United Kingdom by MacKie (1985 [109]). It was based on seven features: sensory change,
5

diameter >1 cm, lesion growth, irregular edge, irregular pigmentation, inflammation, and
crusting/oozing/bleeding. Argenziano et al. (1998 [3]) compared a 7-Point Checklist system
based on simplified epiluminescence microscopy (ELM) pattern analysis to ABCD and found it
improved sensitivity and specificity and required less experience to use. Henning et al. (2007
[77]) introduced the CASH system (color, architecture, symmetry, and homogeneity).
The 1990’s and especially the 2000’s decade saw increasing use of learning methods to
distinguish melanoma tumors based on shape and other characteristics. For example, Claridge,
Hall, Keefe, & Allen (1992 [28]) used shape analysis to classify melanoma, and Ercal, Chawla,
Stoecker, Lee, & Moss (1994 [45]) used a machine learning method to distinguish melanoma
from benign tumors using shape and relative tumor color. The more recent work by Lee &
Claridge (2005 [100]) introduced the predictive power of the Irregularity Index in the diagnosis of
malignant melanoma. Table 1 of the Rigel et al. study (2010 [133]) also identified systems
including image analysis and pattern recognition in the 2000’s. Table 2 of the same study
compared sensitivity, specificity, and diagnostic accuracy of various dermoscopy diagnostic
algorithms. MelaFind, a “noninvasive and objective computer-vision system designed to aid in
detection of early pigmented cutaneous melanoma” (Monheit et al., 2011 [114]) was approved for
use by the U.S. Food and Drug Administration (FDA) after a successful prospective phase III
clinical trial. The last 10 to 15 years has also seen a proliferation of research incorporating
genomic as well as genetic data for use in classification of melanoma. The findings by Viros et
al. (2008 [166]) incorporated mutation status of oncogenes BRAF and NRAS along with
histological features, and showed the BRAF mutations correlated well with morphological
features and found that there were “significant survival benefit… for patients who, based on their
age, were predicted to have BRAF mutant melanomas in 69% of the cases”. In the previously
cited Segura et al. work (2010 [147]), a microRNA (miRNA) signature was developed “whose
overexpression was significantly correlated with longer survival”. Several learning methods were
used in this study including Nearest Shrunken Centroids or NSC (Tibshirani, Hastie, Narasimhan,
6

& Chu, 2003 [161]), Support Vector Machines (SVM), Adaboost with classification trees (Freund
& Schachter, 1996 [57]), and Random Forests. This study also incorporated Pre-validation (PV),
developed by Tibshirani & Efron (2002 [159]), to compare the added value of genomic covariates
in classifiers using traditional prognostic indicators.
Use of Classification to Predict a Subset of Patients by Identifying Sources of Heterogeneity
Treatments specific to melanoma and applicable to a subset of patients have more recently
been coming onto market. For example, subsequent to the findings in Viros et al. (2008 [166]), a
treatment Vemurafenib, for a subset of patients having melanoma with BRAF V600e mutations
(Chapman et al., 2011 [24]) was approved by the FDA. In the year prior, Ipilimumab was
approved by the FDA for treatment of metastatic melanoma (Hodi et al., 2010 [79]). Saenger &
Wochok (2009 [139]) had previously shown that heterogeneity is present in patient response to
Ipilimumab. Moreover Freidlin, Jiang, & Simon (2010 [55]) stated that “due to the molecular
heterogeneity of most human cancers, only a subset of treated patients benefit from a given
therapy. This is particularly relevant for the new generation of anticancer agents that target
specific molecular pathways.” At the same time, relapse of patients or a subset of patients under
these new treatments remains a challenge. Treatment combinations are one avenue being
explored (Tuma, 2012 [162], and Vanneman & Dranoff, 2012 [163]). As pointed out by Freidlin
et al. (2010 [55]), “Genomic … technologies … provide powerful tools for identifying a genetic
signature for patients who are most likely to benefit from a targeted agent”.
Purpose of Chapter
The purpose of this study is to carefully review and examine nonparametric classification
methods in order to understand and best use these methods for treatment subset prediction. Each
method uses a measure of distance to make classification decisions. Proper understanding of these
classification-specific distances facilitates their use in prediction of sensitive patients.

7

Organization of Chapter
The remainder of this chapter is organized as follows: Section 2 addresses notation and
definitions. Section 3 covers nested cross validation methods to estimate and reduce prediction
error. Section 4 outlines nonparametric DR methods for classification. Nonparametric
classification methods are in Section 5. Section 6 highlights generalizability of classification
methods. Discussion and conclusions are in the penultimate section, and Section 8 highlights
challenges and future directions.
2. Notation and Definitions
Subscripts D and V denote training and validation sets respectively, and nD and nV denote
their sample sizes; yi denotes a categorical or a continuous response for the ith subject,

i  1,..., n; n  nD  nV . However when class is the outcome variable, then gi  1 denotes the
disease or relapsed class, and gi  0 or -1 denotes the other class; covariate vectors

xi  {xi1 , xi 2 ,..., xim } and zi  {zi1 , zi 2 ,..., zi }, where

 p  m , denote respectively the clinical

and high-dimensional covariate vectors for the ith subject. The covariate vector for the ith subject
is then {x i , zi } , and the vector for the ith subject consists of the class-covariate vector pairing

{gi ,{xi , zi }}, i  1,..., nD . In the training set ˆ k denotes the average of the kth feature, ˆ gk
denotes the average of feature k for class g, and ˆ gtk denotes the average of feature k for class
g and treatment arm t, where t  1 denotes an enhanced treatment, and t  0 denotes standard
treatment or control.
The term feature refers either to covariates or functions of covariates. For example in the
model E (Yi )  0  1 log( xi1 ), the term log( xi1 ) is used in place of the identity term and is
therefore both a covariate and a feature. However in the equation:

E (Yi )  0  1 xi1  2 log( xi 2 ), the term log( xi1 ) is used in addition to the identity term and is
therefore only a feature. Features may also be functions of several covariates. For example, in the
8

equation E (Yi )  0  1 xi1  2 xi 2  ...m xim   1 zi1  zi , a Feature Extraction (FE)
method could extract a smaller number of features from the covariates.
The term interaction refers to a statistical interaction. A statistical interaction between two
features indicates that the effect of one feature on the response depends on the level of the other
feature. Higher-order interactions are interactions between more than two features. Epistasis
refers to situations in which gene interactions are present while the corresponding main effects
are small. Cordell (2009 [19]) provides an in-depth review of gene-gene interactions. Table 1
provides a list of acronyms, together with definitions and sections where they are used.
Table 1: List of acronyms, definitions, and sections where acronyms are used.
Acronym
Associated Words
Description
ASD

Adaptive Signature Design

Class of Methods to predict
patients sensitive to treatment

CV
DLLR
DR
FE
FS
HTD
KDA

Cross Validation
Difference in LLR
Dimension reduction
Feature Extraction
Feature Selection
High throughput data
Kernel Density Analysis

KNN

K Nearest Neighbors

LLR
LR
LRT
MDR

Log Likelihood Ratio
Likelihood Ratio
Likelihood Ratio Test
Multifactor Dimensionality Reduction

mRNA
miRNA
NSC
OR
PLS
PV

Messenger RNA
microRNA
Nearest Shrunken Centroids
Odds Ratio
Partial Least Squares
Pre-Validation

SNP
SVM

Single Nucleotide Polymorphism
Support Vector Machine

Class of DR Methods
Class of DR Methods
Can be used as a nonparametric
classification method
Nonparametric Classification
Method

Nonparametric Classification
Method
HTD classification method
Method of assessing added
value of genomic features to
clinical features
Nonparametric Classification
Method

Sections
1,3-6

1,3-6
5
1,3-5,7-8
2,3
3
1,4
1,5.3,7
1,5.2,7
4,5
4
5
5.1
6
6
1,5.2
4-5
3
1,5
6
1,5.4, 7

3. Nested Cross Validation (NCV) to Estimate and Reduce Prediction Error
Data splitting involves dividing the data into a training set and a non-overlapping validation
set in order to avoid a downward bias of prediction error ( PE ) , which is the probability of an
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incorrect classification. The expected prediction error can be defined in terms of the joint
distribution of G, X and Z as follows (Hastie et al., 2009 [75]):

E ( PE )  E[ L(G , Gˆ ( X , Z ))],
where L is a loss function associated with incorrect classification. If the loss function is 0 for
correct classification and 1 for misclassification, then prediction error can be estimated on the
validation set by:

pˆ E 

nD  nV



i  nD 1

I ( gˆ i  gi ) / nV .

where g i is class membership for subject i, and gˆ i is predicted class membership.
The classification model is built using data on the training set only, and then this rule is
applied to the validation set to predict class outcome, without use of class information on the
validation set even if it is available. Only after the predicted outcomes have been made is class
information used to estimate prediction error. This helps to achieve an unbiased estimate of
prediction error.
However the goal of machine or statistical learning is not just to avoid a downward bias in
prediction error, but also to minimize prediction error. The Adaptive Signature Design or ASD
(Freidlin & Simon, 2005 [54]) incorporates this learning process by optimizing a set of tuning
parameters on the training set. To avoid overfitting, cross validation is performed on the training
set for each set of tuning parameters. A grid search is then used to select the optimal set of tuning
parameters. This final tuning parameter set is then used for prediction on the final validation set.
This approach is called nested cross validation, or NCV.
Methods such as the bootstrap (sampling with replacement, Efron, 1994 [42]) can also be
used. If a bootstrap sample of size nD is used on the training set, an average of approximately
63% of the training set subjects are placed into a nested training set. Some of the training set
subjects are selected more than once, and some are not selected at all. The subjects not selected in
10

the bootstrap sample (the out-of bag or OOB sample) are then placed in the corresponding nested
validation set. This process is then repeated B times, with some method to assure than all
subjects in the training set are included in a nested validation set at least once. The number B is
chosen depending on the classification task at hand. See Pattengale, Alipour, Bininda-Emonds
Moret, & Stamatakis (2010 [122]) for guidance. Since class outcomes for many of the training set
subjects are predicted more than once, a voting or averaging rule is needed to make the final
classification decision. Breiman (2001 [18]) used OOB prediction error together with the
bootstrap in his Random Forests method. Carpenter & Bithell (2000 [21]) provide a tutorial on
both parametric and nonparametric bootstrap methods. Table 2 shows classification-related
methods, including the bootstrap, along with strengths and weaknesses, and related software
packages.
4. Nonparametric Dimension Reduction (DR) in Classification
There is extensive ongoing research involving DR, and as a title of recent review by Fan &
Lv (2010 [47]) implied, the literature involving DR is so extensive that any review of this topic
itself requires a DR technique. The DR step in classification should be in alignment with the
goals of the specific classification problem. Specifically, the goal of DR is to reduce as much as
possible presence of noise while at the same time preserving information relevant to class
outcome. The presence of many noisy features can have a large negative impact on classification
accuracy, and can even reduce accuracy to that of random guessing (Fan & Fan, 2008 [46]).
DR methods can be subdivided into feature selection (FS) methods and FE methods. FS
methods do not change individual features, but merely select a subset of them. FE methods
reduce dimensionality by extracting a smaller number of new features from the existing features.
FE may be needed if pairwise correlations between features are high, or if prior knowledge
favors grouping of features (Fan & Lv, 2010 [47]).
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Table 2: Nonparametric classification and related methods.
Method
MDR

KNN
Naïve Bayes
KDA

Strengths

Incorporates interactions agnostically, including
higher order gene-gene and gene environment
interactions; makes few assumptions; often attains
good classification performance.
Often attains good classification performance; one of
most simple and intuitive methods, one of most widely
used for low-dimensional data
Often improves classification performance by
reducing variance at the expense of some increase in
bias
Adaptable to different underlying distributions, while
still retaining desirable properties of statistical
densities- naturally handles unequal class sizes and
different misclassification costs

12

SVM

Robust (places more emphasis on observations near
class boundary); includes embedded DR methods; can
handle nonlinear boundaries

Classification
Trees

Easy to interpret, handles mixed covariates, naturally
incorporates interactions

Random
Forests

Smooths out cutpoints for continuous covariates,
improved classification performance compared to
classification trees, naturally incorporates interactions,
including treatment interactions;
Bumping (or
Uses bootstrapping to build an ensemble of trees, but
Bump
selects tree with lowest prediction error. Useful for
Hunting)
finding interactions in absence of main effects.
Boosting
Can control order of interactions, often attains good
classification performance, has natural embedded DR,
acceptable speed/good performance in HD with off –
the-shelf software
Bootstrap
Not a classification method in itself, but incorporated
into many classification methods such as Random
Forests to improve classification performance
*base-base package in R

Drawbacks

Requires special modifications to handle
continuous covariates; since it uses best
subset method, it requires prior DR step in
HTD setting.
Does not naturally handle categorical
covariates; requires prior DR step in HTD;
usually requires scaling of covariates.
May not work well when independence
assumption is severely violated.

R packages

Other Packages

knn(class);kknn,

Proc discrim (SAS)
Enterprise Miner
(SAS)
SAS macros
available

MDR

e1071

MDR (open source
on sourceforge.net)

Poor small sample size performance; does not
naturally handle categorical covariates,
requires prior DR step; comparatively high
computational burden inhibits use in DR
steps.
Requires extensive tuning; SVM’s using
kernel functions with inner products may
need a prior DR step since they increase the
dimensional space; SVM does not handle
unequal class sizes as well as KDA; usually
requires scaling of covariates.
May loose information from continuous
covariates; single trees often have poor
classification performance.

density(base*),
kknn,

Proc kde (SAS)

e1071, svmpath

SHOGUN
(http://shoguntoolbox.org/)
Enterprise Miner
(SAS)

rpart

Loses some interpretability compared to
single classification trees.

randomForest

Needs prior DR step in HTD setting. May
lose information from continuous covariates.

prim

Enterprise Miner
(SAS), CART®
Salford Systems),
GUIDE, LOTUS
Random Forest
(Salford Systems)
Enterprise Miner
(SAS)

Loses some interpretability compared to
single classification trees.

gbm, mboost

Enterprise Miner
(SAS)

Requires some increase in computational
costs, though this continues to be less of a
concern with increased computing power.

rms, bootstrap,
boot

Enterprise Miner
(SAS)

Feature Selection Methods for Treatment Subset Prediction
FS methods choose a small number of features, say p*, from the p features. If the goal is to
predict two groups of subjects categorized as “Relapse within 5 years” and “No relapse within 5
years”, a Wilcoxon or t test comparing the two classes for each feature could be used to select the
continuous features which are most highly differentially expressed between the two classes.
These features would then be selected for use in the classification method. However this method
may not be optimal if the goal is to identify a subset of patients whose tendency to relapse
depends on treatment. In this case, a method is desired which specifically preserves information
concerning treatment-gene interactions. For example one could, for each gene, subtract the
difference in gene expression between relapsed and non-relapsed subjects in the control group
from that in the treatment group, and then divide by the standard error. The equation is:

{(ˆ11k  ˆ 01k )  (ˆ10k  ˆ 00k )}/ ˆ k 2 (1/ n11  1/ n01  1/ n10  1/ n00 ), k  1,..., p, where ˆ k 2 is
the estimate for the pooled variance for gene k on the training set, ˆ gtk are class and treatment
arm-specific means for feature k on the training set ( g {0,1}, t {0,1} ), and ngt is the sample
size of subjects specific to class g and treatment arm t on the training set; i.e. -

n00  n01  n10  n11  nD .
Then a tuning parameter could be used to select genes which exceed a specified value (or
absolute value) for this quantity. Such an approach was used in simulations in Freidlin et al.
(2010 [55]).
Categories of Feature Selection Methods
Categories that Saeys, Inza, & Larrañaga (2007 [140]) use for FS methods are the following:
1. Filter, wrapper, and embedded methods
Filter methods such as the Wilcoxon rank sum test, and the ratio of between group to within
group sum of squares (Dudoit et al., 2002 [39]), are independent of the classification method. On
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the other hand, wrapper methods use a classifier method and attempt to achieve optimization by
successively selecting a subset of features for classification. Sequential forward selection (SFS)
(Kittler 1978 [94]), and Recursive Feature Elimination using SVM (RFE-SVM, Guyon, 2002
[156]) are two examples of wrapper methods. The methods described in Section 4 for MDR and
for SVM are also wrapper methods. Finally, embedded methods such as those in NSC, Random
Forests and Boosting, are built into the classification method. Since they are “embedded” in the
classification method, they are more naturally described along with the classification method in
Section 4.
Filter methods are popular because they can be used for any classification method and often
require less computing costs than wrapper methods. Filtering methods may even be needed prior
to a wrapper method being applied for classification methods such as MDR and KNN, which are
more strongly affected by the curse of dimensionality (see Section 4). Many more examples of
each of these three types of DR methods are given in Saeys et al. (2007 [140]).
2. Multivariable and univariable methods
Saeys et al. (2007 [140]) also make a distinction between multivariable and univariable FS
methods. Unlike univariable methods such as the Wilcoxon rank sum test, multivariable methods,
like FE methods, address feature dependencies. They sometimes also take into account feature
interactions. For example the variable importance measure (VIM) used in Classification Trees,
Random Forests and Boosting (all outlined in Section 4) can be used as a multivariable FS
method that attempts to rank the importance of each feature. As used in trees and Boosting, VIM
ranks each variable/feature based on the number of times it is selected in each tree and the
amount of reduction in prediction error that results. Further details are given in Section 4.5. This
VIM can be easily extended to Random Forests (Section 4.6.1) by averaging over all the trees in
the forest. However Random Forests uses a different VIM which involves permuting each
splitting variable in a tree and recording the decrease in accuracy. This permutation method
nullifies the effect of the feature while keeping the other features. Hastie et al. (2009 [75])
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showed that this permutation method differentiates between features less clearly than the other
measure. Also they pointed out that permuting a feature is not the same as leaving it out, since
when a feature is permuted, there is no opportunity for another feature to take its place in the
split.
Lunetta, Hayward, Segal, & Van Eerdewegh (2004 [108]) claimed that this VIM permutation
method “takes into account interactions among variables without requiring model specification”.
At the same time they also discovered that a much larger number of trees are needed to achieve
stable estimates of VIM with Random Forests. However Winham et al. (2012 [173]) found that
the permutation method had power to detect interactions in low dimensions, but did increasingly
poorly as the dimension increases. For HTD, it captured only those interactions associated with
strong main effects. They also pointed out that in the Lunetta et al. study “the multiplicative
models …have strong marginal components, indicating that the improved performance may be
due to the marginal rather than non-linear association”.
The RFE-SVM method mentioned earlier is a multivariable FS method. This method
recursively eliminates features in an SVM one or more at a time using weights derived from the
SVM. In the Guyon study (2003 [69]) it outperformed univariable FS methods. A contributing
factor was that it avoids selecting a redundant set of features. Wang et al. (2005 [169]) reviewed
multivariable methods including CFS (correlation based feature selection, Hall, 1999 [70]), and
ReliefF (Robnik-Siko & Kononenko, 2003 [137]). They found that ReliefF accounts for genegene interactions. This method is also briefly highlighted in Section 4.2. CFS is also a
multivariable method, but it seeks a subset of features highly correlated with class outcome and
uncorrelated with each other (Liu, Li, & Wong, 2002 [102]).
It is important to distinguish between feature-feature dependency, association of features with
class outcomes, and feature-feature interactions. Features may be highly dependent with respect
to each other and yet have no association with class outcome. CFS seeks out the reverse situation,
which can also be true. In turn, features associated with class outcomes may or may not include
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feature-feature interactions. That is, an individual feature in a group may have a strong
association with class outcome, but changing the level of that feature may not influence the effect
that other features have on class outcome. Finally features which are independent of each other
may still have highly significant feature-feature interactions. These distinctions are sometimes
lost, or at least not sufficiently clarified, in the literature (Saeys et al., 2007 [102]).
Multivariable methods, since they take into account feature dependencies or feature
interactions, search over a much higher dimensional space than p unless the search is restricted in
some way. Therefore unrestricted multivariable methods may not be appropriate for an initial
large scale DR step. Table 3 shows the relationship between number of covariates p and number
of possible 1st , 2nd and 3rd order interactions. This relationship also holds for best subsets
selection and other unrestricted multivariable DR methods. Fan & Fan (2008 [46]) and Fan & Lv
(2010 [47]) provide more guidance and details for selection of FS methods.
Table 3: Relationship between number of features and number of possible interactions.
Order of interaction
P

1

2
6

20*10

3
9

26*1012

5000

12.5*10

10000

50*106

166*109

420*1012

20000

200*106

1.3*1012

6.7*1015

40000

800*106

11*1012

107*1015

Nonparametric FE
FE methods extract a smaller set of features by combining information from the existing
features, while containing that information in fewer dimensions/features. FE can be traced back at
least to principle components, introduced by Pearson (1901 [124]). This is perhaps one of the
oldest and most well-known and commonly used methods. Several nonparametric FE approaches
are briefly described below.
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1. Multidimensional Scaling
Multidimensional scaling (MDS), proposed by Richardson (1938 [132]), extracts a lowerdimensional representation of a pairwise distance between features. An example of a pairwise
distance is difference in wine tasting scores between raters. Bittner et al. (2000 [11]) used MDS
with gene expression data. A thorough discussion of MDS and related methods such as classical
scaling can be found in Hastie et al. (2009 [75]).
2. Use of Biological Information for FE
Biological information is increasingly being used to facilitate FE. One of many examples
include Gene Set Enrichment Analysis, or GSEA (Subramanian et al., 2005 [154]). GSEA
reduces dimensionality by grouping genomic data into biological pathways or gene sets.
Statistical tests are then conducted on the gene set instead of the individual genes. Efron &
Tibshirani proposed an interesting modification of GSEA called Gene Set Analysis or GSA (2006
[43]), which is implemented in the R package GSA. Tarca, Draghici, Bhatti, & Romero (2012
[155]) introduced a gene set analysis method which down-weights overlapping genes. The
method is implemented in Bioconductor package PADOG. Another widely used publicly
available tool is DAVID (Huang, Sherman, & Lempicki, 2008 [85]). DAVID includes a “Gene
Functional Classification Tool” that can be used as part of an FE method. Winter et al., (2012
[174]) recently proposed an adaptation of Google’s PageRank (Page, Brin, Motwani, &
Winograd, 1999 [119]) called NetRank which combines correlation of genes with class together
with their importance in the TRANSFAC transcription factor network outlined by Matys et al.,
(2006 [112]) to rank genes as part of a DR step in a classification method. For a review of use of
biological information for DR, see Moore, Asselbergs, & Williams (2010 [115]).
3. Clustering Used Together With Feature Extraction
One method often used as part of an FE approach is clustering. Clustering methods group
similar objects together. See Gan, Ma, & Wu (2007 [62]) for an in-depth review of clustering
methods. Some clustering algorithms are identified in Figures 1a and 2. Clustering is often used
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with HTD. Pittman et al. (2004 [126]) used clustering to group genes. Metagenes were then
extracted from these groups using FE. The metagenes were then used as features in the
classification method. References for development of clustering methods shown in Figure 2
include [50, 52, 67, 103, 151, 170].
Table 4 provides a list and description of some nonparametric DR methods, including
software implementations. For more detail about FS methods including filter, wrapper, and
embedded methods, and univariable and multivariable FS methods, see Saeys et al. (2007 [59]).
For a review of biological information for DR, see Moore, Assselbergs, & Williams (2010 [52]).
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Table 4: Some Nonparametric Dimension Reduction Methods.

DR Method

Examples

Description

FS Univariable

Wilcoxon test
BSS/WSS

FS Multivariable

CFS

Ranks features based on Wilcoxon test.
Ranks features based on ratio of Between-Sum-of-Squares to Within-Sumof-Squares (Dudoit, 2002).
Correlation Based FS. Seeks a subset of features highly correlated with
outcome and uncorrelated with each other (Liu, Li, Wong 2006).
See Robnik-Siko and Kononenko, 2003 and Wang, Tetko, Hall and others,
2005.
FSelector (Romanski, 2012), Sure Independence Screening (Fan and Lv,
2008), caret (Kuhn, 2013).
Uses a classifier method to select the best subset of features from a larger
set of features (Richardson, 1938), also see Hastie et al., 2009, Bittner et al.,
2000. Computationally impractical for large p.
The classification method itself incorporates a feature ranking or dimension
reduction method.
For classification and regression trees; easily extendable to Random Forests
and Boosting; bases importance of each variable/feature on the number of
times it is selected in each tree and the amount of reduction (improvement)
in prediction error. The relative importance of each variable uses the square
root of the VIM and scales them by using 100 for the most important
variable.
Multi-Dimensional Scaling. Extracts a lower-dimensional representation of
a pairwise distance between features.
Gene Set Enrichment Analysis. Reduces dimensionality by grouping
genomic data into gene sets or biological pathways (Subramanian, Tamayo,
Mootha and others, 2005).
Gene set Analysis. Adaptation of GSEA, Efron and Tibshirani
Pathway Analysis with Down-weighting of Overlapping Genes, (Tarca,
Draghici, Bhatti and others, 2012).
Includes a Gene Functional Classification Tool that can be used as part of
an FE method, (Huang, Sherman, and Lempicki, 2008).
Adaptation of Google’s PageRank which combines correlation of genes
with class together with their importance in the TRANSFAC transcription
factor network (Matys, Kel-Margoulis, Fricke and others, 2006).

ReliefF
Other FS and FS
software
Wrapper Methods

Best Subset Selection

Embedded Methods
Variable Importance
Measure
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FE

MDS

Biologically Based
FE

GSEA
GSA
PADOG
DAVID
NetRank

R/Bioconductor
Software

Other
Software

RWeka,

WEKA

FSelector, SIS, caret
leaps

Proc phreg,
proc reg (SAS)

randomForest

Proc split
(SAS)

cmdscale (R base),
isoMDS(MASS)
GSEABase, GSEAlm,
limma

Proc mds
(SAS)

GSA
PADOG

DR- Dimension Reduction; FS – Feature Selection; SVM-Support Vector Machine; VIM-Variable Importance Measure

DAVID
GUILD

5. Nonparametric Classification Methods
5.1 Multifactor Dimensionality Reduction (MDR)
MDR (Ritchie et al. (2001 [135]) was originally developed to detect multi-locus gene-gene
and gene-environment interactions associated with disease. Lou et al. (2007 [47]) extended it to
include continuous covariates. Figure 3a shows an example where the number of loci is equal to
2, and each locus has 3 genotypes. In this example there are nine possible loci-genotype
combinations. The upper left cell of Figure 3a represents the AA-BB combination. The steps for
MDR are:
1. In each cell the proportion of disease versus disease-free individuals are calculated.
2. A single cut-off is then found to identify high-risk vs. low-risk cells using nested CV.
3. The optimal number and combination of loci on the training set is determined using best
subsets.
4. Then prediction error is estimated on the final validation set using the final model chosen.
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Figure 3a and b: Use of MDR to determine high-risk loci-genotype combinations on a training set, for
purposes of classification.
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MDR and DR
Richie et al. (2001 [135]) claimed that MDR is a DR method which reduces a p-dimensional
factor space to a one-dimensional space by categorizing each possible multi-locus genotype
combination as high-risk or low-risk. However Park & Hastie (2008 [120]) challenged this
assertion on three fronts:
1. For every k less than or equal to p, MDR searches for the optimal k loci-genotype
combination.
2. MDR searches for the optimal number of k factors.
3. MDR searches for the optimal cutpoint to classify individuals in each loci-genotype
combination into high or low risk.
They showed through simulation that the effective degrees of freedom are actually much
greater than 1.
Advantages and Disadvantages of MDR
1. Since proportions are estimated for each combination, there is no assumption of linearity, and
the degree of interaction is determined agnostically- that is without any linearity assumptions
or hierarchy regarding main effects and interactions.
a. The advantage of this is that higher order interactions between loci are estimated
without first having to account for main effects. This is a claimed advantage in the
presence of epistasis.
2. The order of interaction is restricted to k-1 by the number of features k included in the model.
a. There may be some advantages in restricting the order of interactions to be much less
than the number of features. In Section 4.6.2 an ensemble method is discussed which
follows this approach.
3. Figure 3b shows how MDR can be extended from detection of gene-gene interactions or
gene-environment interactions in a case-control setting to gene- treatment interactions in a
clinical study.
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4. Generalized MDR, or GMDR (Lou et al., 2007 [106]) broadened use of MDR by allowing
for both continuous and discrete covariates, as well as continuous phenotypes.
5. Ritchie, Hahn, & Moore (2003 [136]) found that in the presence of 50% genetic
heterogeneity, the power of MDR is very limited and stated that “extending MDR to address
genetic heterogeneity should be a priority”.
6. MDR is strongly affected by the curse of dimensionality. If each of p loci has 3 genotypes,
then the number of table cells for which proportions need to be calculated can be as large as
3p. Therefore in presence of HTD DR methods may be needed before applying MDR
(Cordell, 2009 [30]). Methods such as Genetic Algorithms (Holland, 1975 [82]) which do not
require an exhaustive search have also been used with MDR in an attempt to address this
issue.
7. Software is readily available for MDR and GMDR (http://sourceforge.net/projects/mdr/
accessed 10/28/2012).
8. The method is straightforward, and it makes few assumptions regarding interactions. It is
often used as a standard for gene-gene interactions involving SNP’s (single nucleotide
polymorphisms). It has also been used as a complement to logistic regression.
MDR and Logistic Regression
Ritchie et al. (2001 [135]) claimed an advantage of MDR over logistic regression in the
presence of epistasis since main effects do not need to be accounted for first. Logistic regression
used for classification (LCA) is a parametric method. However at this point it is interesting to
note that LCA using one loci-genotype cell as a reference, and dummy variables for every other
loci-genotype combination, could be used to mimic the MDR approach. Cut-offs could be
determined in a similar manner, and inclusion of continuous covariates could be included without
need for development of additional methods. Comparisons with other genetic models could then
also be made using logistic regression; for some guidance see for example Sasieni (1997 [141])
and Freidlin, Zheng, Li, & Gastwirth (2002 [53]). Methods to account for heterogeneity, such as
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the quasi-likelihood approach for inclusion of a dispersion parameter (McCullagh & Nelder, 1989
[113]), are also available.
MDR requires no modification to be used as a treatment subset prediction method for
categorical factors. One simply uses treatment as an environmental factor, as shown in Figure 3b.
See Table 2 for further information on MDR. Park & Hastie (2008 [120]) provide an in-depth
review of MDR and also propose a penalized logistic regression method for detection of genegene interactions.
5.2 K Nearest Neighbors (KNN)
While the MDR method was first developed for categorical data, K Nearest Neighbors
(KNN) is more naturally used with continuous data. It classifies the ith subject with covariate or
feature vector {x i , zi } in the validation set based on the K subjects with feature vectors nearest
to it in the training set. Nearness is based on a distance metric for the subject-specific feature
vectors, such as Euclidian distance, Mahalanobis distance, absolute value (Manhattan) distance,
or 1 minus correlation (Dudoit et al., 2002 [39]). The class assigned to the subject in the
validation set is based on majority class vote of the nearest subjects in the training set. For this
reason K is usually chosen as an odd integer to avoid ties. Pre-processing of data is important for
KNN since most distance measures used do not take into account variance. One method is to
scale each feature so that it has overall mean 0 and unit variance (Hastie et al., 2009 [75]); K can
be chosen through methods such as nested CV; K=1 or K=3 are common choices.
As with MDR, a separate DR step is needed in an HTD setting before applying KNN. Used in
this way, KNN outperformed most alternatives in the Dudoit et al. (2002 [39]) comparison study.
See Table 2 for KNN strengths, weaknesses and software.
Distance Measures for K Nearest Neighbors
The proportion of nearest neighbors in class g  1 is used as a distance measure for
classification in the KNN method. R Code in supplemental material shows how this distance can
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be extracted. The distance of the K nearest neighbors for each class may also be used as a
distance measure. If the K nearest neighbors in class g  1 are closer to subject i than the K
nearest neighbors in class g  0, then this distance could be used to allocate subject i to class

g  1 . Section 7 shows how these distances can be applied to treatment subset prediction.
Classification Methods and Clinical Covariates
Handling of mixed variables is not regarded as a strength for KNN. However the PV example
in the work by Tibshirani & Efron (2002 [159]) used the following approach to combine genomic
and clinical covariates:
1. An NSC predictor (Tibshirani e al. 2003 [161]) is developed using CV on the genomic data
only.
2

The NSC predictor is then included as a feature, along with clinical covariates in a logistic
regression model over all the data set.

2. The added value of the genomic NSC feature is then evaluated in the logistic regression
model.
The authors proposed a bootstrapping procedure to address issues associated with effective
degrees of freedom. Hofling & Tibshirani (2008 [81]) and Chang et al. (2005 [23]) also proposed
modified PV methods. Approaches such as PV could be used to combine clinical covariates and
HTD features in a classification method for treatment subset prediction. There is nothing
restricting PV to HTD classifiers such as NSC.
5.3 Kernel Density Analysis (KDA) Used for Classification
KDA can be thought of as an extension of KNN (Hastie et al., 2009 [75]). A nearest neighbor
kernel density is a non-smooth kernel density.
Univariable Kernel Density Estimation
Kernel Densities are nonparametric densities formed through use of kernel functions. A onedimensional kernel density can be expressed as:
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1 n  xi1  x0 
fˆ ( x0 ) 
K 
,
nb i 1  b 
where n is the sample size, K is the kernel, b is the bandwidth, x0 refers to a point in this onedimensional covariate space, and xi1 refers to a one-dimensional covariate vector for the ith

 | xi1  x0 | 
 , where  is the probability density
b



subject. The Gaussian kernel is Kb ( x0 )   

function for the Gaussian distribution. For more details see Venables & Ripley (2002 [165]) and
Hastie et al. (2009 [75]).
Univariable Kernel Density Analysis for Classification
To use KDA for classification with one feature, the densities and prior class probabilities
must be calculated for each of the classes. If the feature is genomic, the equation is

LRi 

Pr( g  1, zi1 ) Pr( g  1) Pr( zi1 | g  1)

.
Pr( g  0, zi1 ) Pr( g  0) Pr( zi1 | g  0)

If class densities and probabilities are estimated from the training set, the ratio is estimated as

LRi 

ˆ1 fˆ ( zi1 | ˆ1 )
, where ˆ g {ˆ1 , ˆ0 } are the prior class probabilities estimated from the
ˆ0 fˆ ( zi1 | ˆ0 )

training set, and ˆg {ˆ1 ,ˆ0 } are the vectors of class-specific parameters used to form the
density, such as bandwidth and sample size, again calculated from the training set for each class
g. A cut-off of 1 can be used for the two classes, or it can be based on CV.
Note that this ratio is the distance measure used to make a classification decision. A ratio of 1
indicates a subject on the border between the two classes, and ratios near 0 or much greater than 1
indicate stronger evidence for the subject being in one of the two classes. The log of this ratio,

LLRi , can also be used, in which case the class border is 0, and large positive or negative values
indicate stronger evidence.
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Numeric Example
In the training set, 30 patients responded to treatment and 30 patients did not. There is one
value for gene expression for each patient. Gene expression for non-responders is, after
appropriate normalization, normally distributed with mean 0 and standard deviation 1. For
responders (class g  1 ), it is normally distributed with mean 1 and standard deviation 2. Now on
the validation set class is unknown for patient i, but gene expression=1.5. Using set.seed(234) and
default settings for functions density (for kernel density calculation) and approxfun in R (version
3.02) for interpolation between density values:

LRi 

ˆ1 fˆ ( zi1  1.5 | ˆ1 ) 0.5*0.1915

 1.36.
ˆ0 fˆ ( zi1  1.5 | ˆ0 ) 0.5*0.1408

Since the ratio is greater than 1, and class sizes are equal, the patient can be predicted to respond
to treatment. The class boundary ( LRi  1 ) occurs at about z  1.298 .
Multivariable Kernel Density Analysis for Classification
The naïve Bayes assumption is that features within a class are independent. Extension of
KDA to a multi-dimensional feature space is made easier if this assumption is employed. Various
authors including Hastie et al. (2009 [75]) and Bickel & Levina (2004 [9]) have noted the success
of naïve Bayes methods, despite the fact that the independence assumption is not generally true.
Using this assumption, densities can be calculated conditional on class for each feature
individually, and then the p-dimensional density is the product of the individual densities. The
density conditional on class g for a new subject with genomic feature vector zi  zi1 ,..., zip is
then fˆ (zi | ˆg ) 

p

 fˆ ( z
k 1

ik

| ˆgk ), assuming independence. Individual subjects can be allocated as

before using the plug-in likelihood ratio LRi 

ˆ1 fˆ (zi | ˆ1 )
. Densities can also be based on a
ˆ0 fˆ (zi | ˆ0 )
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combination of clinical and genomic features {x i , zi }, and categorical features as well as
continuous features. Categorical features can be incorporated using histogram estimates (Hastie et
al., 2009).
Kernel Density Classification for Two or More Classes
If there are two or more classes g  0,1,..., G 1, then subject i can be allocated to the class
with the highest posterior probability; i.e. -



 ˆ fˆ (z | ˆ ) 
 g

i
g
gˆ i  arg max g {Pr post , gi }  arg max g  G 1
 , where  g is the prior probability for
  ˆ g fˆ (zi | ˆg ) 


 g 0

class g. Details can be found in Hastie et al. (2009 [75]). Now denote Prpost ,i as the posterior
probability for class g=1 for subject i. Then Pr post ,i is a distance used to make a classification
decision. For two classes, a Pr post ,i  0.5 is on the border between the two classes. Probabilities
away from this boundary in either direction indicate stronger evidence for one of the two classes.
Approaches employing both LLRi and Pr post ,i distances are applied to treatment subset
prediction in Section 7.
Other KDA Methods
There are also other approaches besides naïve Bayes to obtain multivariable kernel densities.
Wand and Jones (1993 [168]) compared smoothing parameterizations for bivariable kernel
densities. The R package ks (Duong, 2007 [41]) allows kernel smoothing from one to 6
dimensions. The function kda.kde in package ks performs KDA for up to 6 dimensions. Still
another KDA approach involves difference in densities. This approach can be traced back to Hall
and Wand (1988 [71]). More recently Kim and Scott (2010 [93]) introduced L2 kernel
classification for difference in densities. For dimensions p>15, they introduced a regularization
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parameter, which their simulations showed enables performance similar to other HTD methods
such as SVM.
5.4 Support Vector Machines
The KDA method uses kernel functions to estimate class densities, which can then be used to
find a decision boundary. SVM’s, on the other hand, use kernel functions to find a decision
boundary between the two classes. When two classes are linearly separable, a decision boundary
is found that maximizes the separation between the two classes. See Hastie et al. (2009 [75]) and
Cristianini & Shawe-Taylor (2000 [32]) for more detail.

Figure 4: A support vector machine for a 2-dimensional feature space: (gene expression for gene 1 and
gene 2) which linearly separates the two classes, which are represented by the “Δ” subjects and the “o”
subjects. In this case there is a separating hyperplane, meaning that there are no subjects on the wrong side
of the line. Therefore only three subjects-specific feature vectors are needed as support vectors. In this case
they are z 4 , z 9 , and z 12 .

Support Vector Machines for Two Linearly Separable Classes
2
1. Figure 4 shows training set data points consisting of the fixed zi vectors, where zi   .

Extension to higher dimensions  p is straightforward. The zi are the feature vectors for each
29

subject i in the training set, i  1,..., n1; n1  6 for the o class, and i  n1  1,..., n1  n 2 for the
Δ class.
2. The horizontal and vertical axes represent gene expression for gene 1 and gene 2. Quadratic
programming is used to conduct a search to find the three support vectors, which are the
three subject-specific feature vectors that minimize Euclidian distance

w in the equations

for the two margin boundaries passing through the three support vectors ; the equations are

w'z  b  1 and w'z  b  -1 .
3.

In Figure 4 the three support vectors are z4 , z9 and z12 .

4. The decision boundary is then the line w'z  b  0 .
5. The classification decision for subject i in the validation set is then gˆ (zi )  sign(w'zi  b) .
From this it follows that the distance used to make a classification decision for subject i in the
validation set is di  w'zi  b. A large magnitude distance in the negative/positive direction
indicates subject i is further away from the class boundary, and offers stronger support for the
subject being in one of the two classes.
Numeric Example
Subject i in validation set has gene expression 1.1 and 1.3, for two genes, after appropriate
normalization and scaling. Also from the training set are calculated coefficient vector

w  (0.5,1.8) ' , and b  3. Then w'zi  b  4.79, and gˆ i  sign(4.79)  1. R code which
calculates coefficients and classification distance is included in supplemental material.
Support Vector Machines for Non-Linearly Separable Classes
In the case where it is not possible to linearly separate the two classes, it is possible to allow
additional support vectors on the wrong side of their respective margin boundaries with slack
variables which are the distances of the corresponding support vectors from their respective class
margin boundary. In this situation the same approach is used to find the support vectors as before,
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but with the additional constraint of minimizing the slack variable distances using a penalty term.
More detail is given in Hastie et al. (2009 [75]). If the decision function itself is nonlinear one can
often find a linear separating hyperplane in a higher dimensional space using specific kernel
functions. See Vapnik (1998 [164]) for more details. Chen et al. (2008 [25]) compared various
SVM methods with MDR in their ability to detect gene-gene interactions. More detail is given in
Hastie et al. (2009 [39]).
5.5 Classification and Regression Trees
Classification and regression trees are a way of recursively partitioning data, one feature at a
time, into more homogeneous subgroups. The root node is at the top of the tree and contains the
entire data set. Starting from this root node, the data is recursively partitioned into daughter nodes
which contain finer and finer subsets of the data, one feature at a time, based on which feature
subsets the previous node into the most homogeneous subgroups. The terminal nodes contain the
final partitions for all the data. Each subject in a validation set can then be allocated into one and
only one of these final partitions based on a classification tree grown on a training set.
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Figure 5: Flowchart of ASD nested cross validation method. *Training set can refer both to Stage 1 patients, and
to the training sets nested within the Stage 1 data. Similarly, validation set can refer to the corresponding nested
validation sets in the Stage 1 data, or to the final validation set – the Stage 2 patient data.

Feature and Cutpoint Selection
Feature selection for partitioning a node is performed using criteria such as reduction in
impurity. Impurity measures are at a maximum when the two partitioned daughter nodes have the
same proportion of subjects in each of the two classes. Impurity is at a minimum when the two
daughter nodes perfectly separate the two classes. Reduction in impurity is measured by the
difference in impurity between the parent node and the average impurity of the daughter nodes.
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Examples of impurity measures include the Gini index (Gini, 1912 [64]) and entropy (Hastie et
al., 2009 [75]).
Statistical Interactions in Classification Trees
One advantage of classification trees often pointed out is that they are able to identify
complex interactions, including interactions involving different types of covariates, such as
interactions between treatment, clinical covariates, and HT covariates. In fact early development
of classification trees were motivated by interaction detection (Morgan & Sonquist, 1963 [75]).
Strobl, Malley, & Tutz (2009 [152]) provide an in-depth review of statistical interactions in trees.
If a tree contains only one split, then no interaction can be included since only one feature is
used in a split. Such a tree is often called a stump and has a depth h  1. However if a tree
contains two splits, then a two-way interaction is involved if the change in class proportions due
to the second split depends on the partitions for the first split. A concise illustration is shown in
Figure 4 of Strobl et al. (2009 [152]). Interactions may also be present when a split occurs in one
daughter node, but not the other. Trees with greater depth (more recursive partitions) are capable
of including successively higher order interactions.
If specific interest lies in treatment-covariate interactions to identify a subset of patients more
prone to relapse, trees based on unmodified CART® (Breiman, Friedman, Olshen & Stone, 1984
[15]) have limitations since they may model interactions that are not of primary interest. However
Schmoor, Ulm, & Schumacher (1993 [145]) modified the approach. They first used CART to
identify covariates associated with disease prognosis. They then tested for treatment
heterogeneity within the subgroups identified by these covariates, but results were not significant.
Finally they modified the splitting procedure and based it on treatment interactions. Using this
approach they found that Karnofsky Index and age had significant treatment interactions.
Karnofsky Index was not included in the first approach because its main effect was not strongly
associated with prognosis. Later Loh (2002 [104]) proposed a method called GUIDE which
enables detection of local interactions in regression trees. Su, Tsai, Wang & Li (2009 [153])
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further developed use of interaction trees. See Loh (2011 [105]) for a review of classification and
regression trees which includes interaction trees.
5.6 Ensemble Methods
“Plans fail for lack of counsel, but with many advisers they succeed” (New International
Version, Prov. 15:22). This is the basic idea behind ensemble methods, which combine classifiers
in different ways to improve stability and performance of individual classifiers. Some ensemble
methods are reviewed below.
5.6.1 Random Forests
Individual classification trees can be unstable, since small changes in the data can have a
large effect on the predicted class labels. Also the order of the covariates or features used to split
nodes can have a large influence on the predicted class label. Random Forests is an ensemble
classification method that incorporates tools such as bootstrapping and Random Features (random
sampling of features selected for potential splitting of a node; Breiman, 1999 [17] ) to improve
stability of classification trees. The steps are as follows:
1. Divide data with n subjects into training set with nD subjects and validation set with nV
subjects.
2. From training set with sample size nD , use bootstrapping to generate a nested training set of
size nD .
3. From the nested training set grow a tree using an impurity measure to select from a small set
of m candidate random features at each node.
4. Classify each subject not included in the bootstrap sample using this tree.
5. Repeat the above steps to grow B trees.
6. Using the B trees, classify each subject using the majority vote from all the trees.
If the data set is divided up into a training and a validation set, then B trees can be grown on
the training set and used to classify each subject i in the validation set. In that case the
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( ensemble )
( xi , zi )  I ( pi1  0.5) , where I
classification decision for subject i can be written as gˆ i

is the indicator function and pi ,G 1 is the proportion of the B trees that classified subject i into

g  1. In this case the distance used to make the classification decision is pi ,G 1 . A proportion
away from 0.5 and near 0 or 1 indicates stronger support for gi  0 or gi  1. R code is included
in supplementary material which automatically calculates this proportion. The classification



B

 gˆ


( ensemble )
 sign 
decision can also be written as gˆ i

b 1

(b)
i


( x i , zi )  , where gˆ i(b ) {1,1}, and


b = 1,..., B denotes the bth successive classifier. The classification distance is then:
B

 gˆ
b 1

(b )
i

( x i , zi ). A higher magnitude of this quantity in either the positive or negative direction is

then an indication of how far away subject i is from the border between the two classes.
Section 7 shows how these distances can be extended to treatment subset prediction. See
Foster, Taylor, & Ruberg (2011 [51]) for an existing Random Forests method which uses clinical
covariates, including demographic and survey data, to predict a subset of patients having an
enhanced treatment effect.
Bumping and Interaction Effects
Bumping (Tibshirani & Knight (1999 [158]), like Random Forests, uses bootstrapping to
build an ensemble of trees, but unlike Random Forests it selects the one tree with the lowest
prediction error on the training set. If enough trees are used, Bumping can often find a split to
minimize prediction even if are no main effects. An example is given in Hastie et al. (2009 [75]).
Lipkovich, Dmitrenko, Denne, & Enas (2011 [101]) developed a method closely related to
Bumping to predict multiple treatment subgroups in clinical trials.
5.6.2 Boosting
Boosting employs an ensemble of individual classifiers, and each classifier after the first one
is reweighted based on the previous classifier.
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1. The individual classifier is selected from a category of classifiers; for example, logistic
classification trees (Chan & Loh, 2004 [22]).
(1)
2. The first individual classifier, gˆ i ( x i , zi ), has weights initialized for each subject i in the
(1)
training set: wi  1 / nD , i  1,..., nD . This classifier is then fit to the training set using these

wi(1) weights.
( b 1)

3. If subject i is misclassified for the bth classifier, its weight ( wi

) is increased, and subjects

classified correctly have their weights decreased.
4. A coefficient  (b ) is determined for the bth classifier based on weighted classification
performance. Individual classifiers with better performance are given larger positive
coefficients.
5. Subjects in the validation set are then allocated to one of two classes based on the ensemble
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classifier: gˆ i
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gˆ i(b) ( x i , zi )  , i  nD  1,..., nD  nV .


A shrinkage constant  much smaller than 1 has been shown to prevent overfitting. The
equation then becomes:

 B

gˆ i( ensemble )  sign     (b) gˆ i(b) ( x i , zi )  .
 b1

The distance used in Boosting for classification is then 

B


b 1

(b)

gˆ i(b) ( x i , zi ) . Large negative

distances indicate support for allocating subject i into class g  1, and large positive distances
indicate support for class g  1. Differences in this distance across treatment arms may then be
evidence for subject i being sensitive to treatment. R code is included in supplementary material
which calculates the Boosting classification distance for a subject in the validation set.
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More information about Stochastic Boosting and Gradient Boosting can be found in Hastie et
al. (2009 [75]), Friedman (2002 [60]), and Elith, Leathwick, & Hastie (2008 [44]).
Boosting and Interaction Order
As explained in Section 5.5, the order of interactions in a tree is restricted by the depth of the
tree. A tree of depth h allows interactions up to order h  1 . This fact can be exploited in Boosting
to compare models allowing different interaction orders. This can be done by comparing
prediction error of boosted trees of a specific depth to that of boosted tree stumps, which allow no
interactions. Care must be taken to allow a sufficient number of trees to minimize prediction
error. Several authors have indicated that trees with depth in the range of 5 to 9 can be used in
this manner to assess order of interactions.
Boosting and Interpretability
The VIM developed for classification trees can be easily used in Boosting to find the most
influential variables. Elith et al. (2008 [44]) showed partial dependence plots of main effects and
interactions based on VIM. The main effects plots showed the most influential main effects with
other variables fixed at their average value. The same approach was used for contour plots of two
variables to assess interactions. Contour plots which include the two-variable interaction are
compared to contour plots from boosted stump models which cannot include interactions. The
difference in the two plots gives a visual comparison of the importance of the interaction on the
marginal effect.
5.7 Other Methods
A brief mention is given here of some other classification methods which may be used to
identify subsets of patients responding differently to treatment.
Ensemble methods reviewed in this study, such as Random Forests and Boosting, employ
individual classifiers of the same category. Stacking (Wolpert, 1992 [175]) uses an ensemble of
different classifiers, and this approach has been shown to improve performance under many
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situations. Leblanc & Tibshirani (1996 [98]) developed a Bootstrap approach for Stacking. A
related approach is Bundling (Hothorn and Lausen, 2005 [84]), implemented in the R package
ipred (Peters & Hothorn, 2012 [125]). For a recent in-depth review of ensemble methods,
including combination methods, combination learning, ensemble diversity, and many other
approaches, see Zhou (2012 [182]).
Cordell (2009 [30]) reviewed a Bayesian method to assess gene interactions (BEAM, or
Bayesian Epistasis Association Mapping, Zhang & Liu, 2007 [180]). Software implementations
of BEAM can be found at http://sites.stat.psu.edu/~yuzhang/ (accessed 10/13/2012). Huang et al.
(2004 [86]) introduced FlexTree, a tree-structured methods for detecting gene-gene interactions.
This was also compared to MDR and the penalized logistic regression method in the Park &
Hastie (2008 [120]) work. Logic regression (Ruczinski, Kooperberg, & LeBlanc, 2004 [138]) has
been used in sequence analysis and to explore high-order interactions in HTD. Foster et al. (2011
[51]) introduced the “Identical Twins” approach. This method borrows an approach from
counterfactual models (Ginsberg, 1986 [65]). Specifically, it assumes “there are two possible
outcomes for each person (one under each treatment assignment), only one of which can be
observed (Foster et al. 2011 [51]).” The KDA classification method described in Section 4.3 used
a counterfactual approach, as did Rai, Pan, Cambon and others (2013 [129]).
For an introduction to Neural Networks, see Duda et al. (2001 [38]), Hastie et al. (2009 [75]),
and Venables & Ripley (2002 [165]). For an application of Neural Networks to cancer
informatics, see Cruz & Wishart (2006 [33]). For Bayesian Neural Networks ,see Neil & Zhang
(2006 [116]). A Bayesian Neural Network model entered in the NIPS 2003 challenge
(http://nips.cc/) had superior classification performance to Boosting and Random Forests models
(Hastie et al. 2009 [75]). One disadvantage of Neural Networks in a clinical setting is difficulty of
interpretation (Hastie et al., 2009[75]). Chen et al. (2008 [25]) argued that Neural Networks are
not appropriate for study of gene-gene interactions. On the other hand, ensemble methods such as
Boosting can employ Neural Networks as individual classifiers in a way similar to trees. An
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implementation of Neural Networks is found in R package nnet (Venables & Ripley, 2002 [165]).
There is also extensive literature on rule-based and fuzzy rule-based classifiers (Kosko 1993
[96]).
6. Generalizability of Classification Methods
Split sample, CV, and bootstrap methods discussed above are internal validation methods. In
these methods, the same data set used for training is also used for validation and prediction error,
even though paired training and validation sets are themselves non-overlapping. Internal
validation is important and necessarily precedes other more all-encompassing forms of validation.
Altman, Vergouwe, Royston & Moon (2009 [1]) provide an in-depth review of internal and
external validation.
High dimensional genomic and proteomic data magnify challenges associated with external
validation because the field is changing rapidly and platforms, technologies, and methods become
obsolete. For example in the early 2000’s HTD commonly involved messenger RNA (mRNA)
expression. However it has increasingly been shown that miRNA’s, copy number, SNP’s,
proteins, and methylation status play an important role in cancer and melanoma. Next Generation
Sequencing (NGS) platforms are replacing traditional microarray platforms in many applications.
Since NGS often involves count data, this may mean that, in these situations, models for count
data, such as Poisson models, may be used in place of other classification methods.
While developments in all these areas are bringing tremendous opportunity for advancement
in treatments of melanoma and other cancers, they also pose challenges regarding external
validation. Classification methods that are robust to changes in platforms may be more
generalizable. To that end, Maglietta et al. (2010 [110]) proposed a method which involves rules
for selecting sets of genes/miRNA’s.
7. Discussion and Conclusions
The specific ASD described in Freidlin & Simon (2005 [54]) uses weighted voting and single
gene logistic models which include treatment-gene interaction. The tuning parameter set consists
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of a tuning parameter  to select predictive genes from the training set, a tuning parameter R to
determine the cutoff for the magnitude of the treatment arm odds ratio (OR) for a selected gene,
and a tuning parameter H to determine the number of selected genes with OR exceeding R
necessary to predict a patient to be sensitive. More details are given in Figure 5.
In this specific ASD design, the treatment arms OR is used as a distance measure to compare
response to treatment across the two arms. In the ASD implementation by Scher, Nasso, Rubin, &
Simon (2011 [144]) the log hazard ratio was used in the same way. Below are examples of
nonparametric distances used in treatment subset prediction methods.
Treatment Subset Prediction Using Kernel Density Analysis and Random Forests
Distances for KDA used for classification have been described in Section 5.3. For example an

LLR close to 0 indicates a subject on the borderline between the two classes, and large positive
or negative values indicates the extent to which a subject may be in one class or the other. The
difference in the LLR ( DLLR) between the treatment and control group is then a measure of
how sensitive the subject in the validation set is to treatment. The single-gene model is:
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The method for calculating LLRitk is the same as in Section 5.3, except that it is now
calculated separately for each treatment arm, t  1 and t  0, and for each selected gene k. This
in turn necessitates estimated prior probabilities ˆ gt and parameters ˆgtk in place of ˆ g and ˆg ,
as these quantities are now calculated separately not only for each class g, but also for each
treatment arm t (and ˆgtk for each selected gene k), using class and treatment arm-specific
information from the training set. Alternatively, the estimate for the single gene posterior OR is

OR post ,ik 
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is similar to Pr post ,i in Section 5.3 except

it is calculated for each selected gene k and for both treatment arms t  1 and t  0. A high
positive value of DLLRik or of log(OR post ,ik ) is indicative of a positive response in the
treatment arm compared to the control arm for subject i. In a weighted voting method, DLLRik
or log(OR post ,ik ) is calculated for each gene k and for each subject i in the validation set, and if
the number of genes with DLLRik  R is at least H , that subject would be classified as
sensitive to treatment. The same nested CV approach used in ASD could then be employed in this
method. Since the classification distance for Random Forests can also be expressed as a
proportion (of votes), a Random Forests OR can also be employed in the same manner for
treatment subset prediction. However only tuning parameter R may be needed for Random
Forests, since one OR is calculated for each subject, and since the Random Forests embedded
DR method may eliminate need for .
K Nearest Neighbors and Treatment Subset Prediction
The distance employed in KNN is calculated over all the selected features for a subject. This
eliminates need for the tuning parameter H in ASD. However a tuning parameter is still needed
for K ,  , and R. To make a classification decision, KNN uses the proportion of nearest
neighbors in the response class g=1, say pi as a distance. If the proportion is greater than 0.5, the
subject is assigned to the response class, and to the non-response class otherwise. This can be
expressed as gˆ i  I ( pi  0.5). A simple method for treatment subset prediction is to compare
this proportion across the two treatment arms. In this method, the K nearest neighbors are
calculated for both the treatment arm and the control arm. A greater difference in this proportion
over the two treatment arms ( pi1  pi 0 ) is then indicative of patient sensitivity to treatment.
An alternative approach that makes direct use of the distance measure used to select the
nearest neighbors is as follows:
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1. The K nearest neighbors for a subject in the validation set are found for both responders and
non-responders over both training set treatment arms. The total nearest neighbors for a
subject is 4 K .
2. The average distance, say d gti , is calculated for both the K nearest responders and the K
nearest non-responders in each treatment arm.
3. The average distance of the responders is then subtracted from the average distance of the
non-responders for both treatment arms:

d

01i

 d11i    d00i  d10i  .

4. If this distance exceeds tuning parameter R, the subject is predicted to be sensitive to
treatment.
Numeric Example
After appropriate DR and standardization for gene expression, it is found, using nested CV on
the training set, that the optimal values for K and R are 2 and 2.2. Then for subject i in the
validation set, the average distance of the two closest responders on the training set treatment arm
is 2.3, using Euclidian distance. The average distance of the two closest non-responders is 4.4. On
the training set control arm, the average distance for the two closest responders is 3.5, and for



 



non-responders it is 3.3. Therefore d01i  d11i  d00i  d10i  2.1  (0.2)  2.3. Since

2.3  R, subject i is predicted to be sensitive to treatment.
Treatment Subset Prediction Using Support Vector Machines and Boosting
The numeric example given for SVM in Section 5.4 is easily extendable to treatment subset
prediction. The distance d ti is calculated in the same manner as d i in Section 5.4, but with w and
b calculated separately for each treatment arms in the training set. The difference in this distance
between treatment arms is then:

d1i  d0i   di | t  1   di | t  0    w1 ' zi  b1    w0 ' zi  b0  . A tuning parameter similar to
R can be selected using nested CV or bootstrapping on the training set. If this difference in
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distance exceeds R, subject i in the validation set is then predicted to be sensitive to treatment.
The same approach can be used for Boosting, using the Boosting distance. Note that if an
embedded DR method is used, then only tuning parameter R is needed for these methods. An
additional advantage for Boosting (and Random Forests) is that these methods easily handle
mixed covariates, meaning that clinical as well as genomic data can be easily incorporated.
8. Challenges and Future Directions
The no-free-lunch theorem states that no one classification method is optimal under all
situations. Therefore it is beneficial to have a range of different methods for treatment subset
prediction. Treatment interactions have been incorporated into each of the nonparametric methods
reviewed above, but since the classification distance used for each method is unique, the type of
treatment interaction is different for each method, as is the type of DR required. Many aspects of
ASD require further research. For example, instead of a weighted voting method, an average
score could be calculated over all the selected genes. This would eliminate need for tuning
parameter H . Also sensitivity status is a latent variable since some sensitive patients do not
respond to treatment, while some nonsensitive patients do respond to treatment. This results in a
mixture of normal distributions for each class-specific and treatment arm-specific status. An EM
algorithm (Dempster, Laird, and Rubin, 1977 [34]) developed by Bishop (2006 [10]) addresses
this situation. He also developed a Bayesian method which addresses some of the shortcomings
of the maximum likelihood method for mixtures. Finally, many works also highlight the
importance of pathways in heterogeneity. It would be beneficial then to more directly incorporate
pathway analysis into ASD methods. Methods such as these warrant further research using real
data sets and simulation studies to elucidate their performance under various scenarios.
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PARAMETRIC CLASSIFICATION METHODS
1. Some Historical Developments of Parametric Classification Methods
The roots of discriminant analysis date back to before 1936, when Mahalanobis (1936 [111])
introduced the Mahalanobis distance, and Fisher outlined a method which used this same distance
to discriminate between species of iris (1936 [48]). This became known as Fisher’s Discriminant
Analysis (FDA). Welch (1939 [171]) used the likelihood ratio (LR) to show that FDA was
equivalent to Linear Discriminant Analysis (LDA) when maximum likelihood (ML) estimates are
used in place of true parameters. LDA assumes a multivariate normal distribution for the
covariates. Wald (1944 [167]) incorporated prior population probabilities and misclassification
costs.
Other statisticians who played important roles in the early development of discriminant
analysis include Pearson, who proposed a mixture of normal distributions for clustering (1894
[123]), Neyman & Pearson (1933 [117]), who introduced the likelihood ratio test (LRT), and Rao
(1947 [130]). Cox (1966 [31]) played an early role in the development of Logistic Classification
Analysis or LCA (Anderson, 1972 [2]). Quenouille (1949 [128]) introduced the jackknife which
reduces bias by successively leaving out one observation at a time, and Hills (1966 [78]) and
Lachenbruch & Mickey (1968 [97]) introduced a method, closely related to the jackknife, of
estimating error rates by omitting one observation from the computation of the discriminant
function and using that observation to estimate error. This is the leave one out cross validation
(LOOCV) method, which is one example of the more general method of cross validation (CV)
which divides data into non-overlapping training and validation sets to build a model and estimate
error. Lachenbruch and Mickey also pointed out the bias and optimism of the resubstitution
method, which uses the same sample both to build a model and to estimate error.
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These early methods were developed at a time when high throughput data (HTD) was not as
prevalent. HTD typically have tens of thousands or more of features, together with sample sizes
on the order of 100 or less. This situation is often referred to as p  n where p refers to the
features and n refers to the sample size. The early parametric methods mentioned above are not
HTD-capable without some outside help. Many dimension reduction (DR) methods have been
developed for HTD to address this situation. More recent nonparametric machine learning
methods such as Random Forests and Boosting were developed specifically for HTD and have
built-in DR techniques. At the same time, the earlier developed parametric classification methods,
when used in conjunction with suitable DR techniques, often compare favorably to these more
recently developed machine learning methods. For example a modified version of LDA, Diagonal
Linear Discriminant Analysis (DLDA), which ignores correlation between features, outperformed
Boosting and Random Forests in a comparison of methods by Dudoit et al. (2002 [39]) involving
genomic data. Further work by Bickel & Levina (2004 [9]) and Fan & Fan (2008 [46]) showed
reasons why DLDA often outperforms LDA in an HTD setting.
L1 Regularization or L1R (Tibshirani, 1996 [157]) selects at most n features and shrinks
coefficients of selected features towards 0. Thus it provides a way to naturally integrate the DR
and classification steps. In contrast, L2 Regularization or L2R (Hoerl & Kennard, 1970 [80])
shrinks parameter estimates towards 0 or towards a common value, without eliminating any of
them. L2R methods such as those introduced by Ledoit & Wolfe (2004 [99]) improve stability of
covariance matrices. Developments such as these further enabled use of parametric classification
methods in an HTD setting. Applications involving classification include Penalized Discriminant
Analysis (Hastie, Buja, & Tibshirani, 1995 [74]), NSC (Tibshirani et al., 2003 [161]),
Regularized Discriminant Analysis (Friedman, 1989 [58]), MLDA (Modified LDA, Xu, Brock, &
Parrish, 2009 [177]) and penalized logistic regression for gene interactions (Park & Hastie, 2008
[120]).
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Treatment Subset Prediction
In phase III clinical trials, it has increasingly been recognized that treatment agents only
benefit a subset of patients enrolled in these studies. In cases where predictive assays cannot be
developed before a phase III clinical trial, Freidlin & Simon (2005 [54]) proposed the Adaptive
Signature Design (ASD) which predicts a subset of patients more sensitive to treatment based on
gene expression data. Their specific ASD model used weighted voting and single gene logistic
models which include gene-treatment interaction. The tuning parameter set consists of a
parameter  to select predictive genes from the training set, a parameter R to determine the
threshold for the magnitude of the treatment arm odds ratio (OR) for a selected gene and patient
in the validation set, and a parameter H to determine the threshold for the number of selected
genes for a patient in the validation set having a treatment arm OR which exceed R. Subjects
which have at least H selected genes meeting criteria for R are predicted to be sensitive to
treatment. Type 1 error is partitioned between a test for overall treatment effect involving all the
subjects and a test for treatment effect involving only the stage II patients predicted to be
sensitive to treatment. Figure 5 gives more information.
Other recent works in this area include Zhang, Tsiatis, Laber, & Davidian (2013 [179]), and
Zhao, Tian, Cai, Claggett, & Wei (2013 [181]).
Purpose of Chapter
The purpose of this study is first to review and examine parametric classification methods,
focusing on specific distance measures used to make a classification decision. These are specific
to the classification method and are what make the method unique. Then extensions of these
methods to treatment subset prediction can often be made by comparing these distances across
treatment arms. Since no one classification method is optimal in all situations, it is advantageous
to have available different methods for treatment subset prediction.
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Organization of Study
Section 2 covers notation and definitions. Section 3 is a brief introduction to parametric DR
methods, with a focus on treatment subset prediction. Parametric classification models and rules
are outlined in Section 4. Discussion and conclusions are in Sections 5, and challenges and future
work are in Section 6.
2. Notation and Definitions
Notational convention follows that of Part 1 of this review. Subscripts D and V denote
training and validation sets respectively, and nD and nV denote their sample sizes; yi denotes a
categorical or a continuous response for the ith subject. For two classes, gi  1 denotes the disease
or relapsed class, and gi  0 or -1 denotes the other class; for more than two classes,

gi {0,1,..., G  1} ; covariate vectors xi  {xi1 , xi 2 ,..., xim } and zi  {zi1 , zi 2 ,..., zi }, where
 p  m , denote respectively the clinical and high-dimensional covariate vectors for the ith
subject. The covariate vector for the ith subject is then {x i , zi } . In the training set ˆ k denotes the
average of the kth feature, ˆ gk denotes the average of the kth feature over subjects that belong to
the specific class g , and ˆ gtk denotes the average over the subset of subjects in class g that have
also been assigned to treatment arm t , where t {0,1}.
The term feature refers either to covariates or functions of covariates, and the term interaction
refers to a statistical interaction [30]. More detail can be found in Part 1 of this review. Table 5
provides a list of acronyms and definitions used in this chapter.
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Table 5: List of acronyms, definitions, and sections where acronyms are used.
Acronym Associated Words
Description
ASD

Adaptive Signature Design

Sections

CS
CV
DLDA
DLLR
DR
ECM
FE
FDA
FS
HTD
LASSO

Compound Symmetry
Cross-Validation
Diagonal Linear Discriminant Analysis
Difference in LLR
Dimension Reduction
Expected Cost of Misclassification
Feature Extraction
Fisher’s Discriminant Analysis
Feature Selection
High Throughput Data
Least Absolute Shrinkage and Selection
Operator
L1 Regularization
L2 Regularization
Logistic Classification Analysis
Linear Discriminant Analysis
Leave-One-Out Cross-Validation
Likelihood Ratio
Likelihood Ratio Test
Log Likelihood Ratio
Median Absolute Deviation
Maximum Likelihood
Modified Linear Discriminant Analysis
Messenger RNA
microRNA
Nearest Shrunken Centroids
Odds Ratio
Principal Components
Principal Components Analysis
Penalized Discriminant Analysis
Partial Least Squares
Quadratic Linear Discriminant Analysis
Quadratic Discriminant Analysis
Regularized Discriminant Analysis
Shrunken Centroids RDA
Single Nucleotide Polymorphism
Sparse PCA
Sparse PLS

1,3-6
4
5
3-4
4
3
4
3
1,4
1,3

L1R
L2R
LCA
LDA
LOOCV
LR
LRT
LLR
MAD
ML
MLDA
mRNA
miRNA
NSC
OR
PC
PCA
PDA
PLS
QLDA
QDA
RDA
SCRDA
SNP
SPCA
SPLS

Method to predict subset of patients
responding differently to treatment; see Figure
5
See Table 7
See Table 7

Class of DR methods
See Table 7
Class of DR methods
Same as L1R- see Table 6
Same as LASSO - see Table 6
Same as Ridge Regression - See Table 6
See Table 7
See Table 7

Robust regression method
See Table 7
HTD classification method
See Table 6
See Table 7
See Table 6
See Table 7
See Table 7
See Table 7
See Table 7
See Table 7

1,3-6

1,3
1,3
1,4,5
1,4
1
1,4
1,4,5
4,5
4
1,4,5
4
6
6
5.2
1,4-5
3
3
4
3
4
4
4
4
6
3
3

3. A Brief Introduction to Parametric Dimension Reduction with a Focus on Treatment
Subset Prediction
The application of DR methods in an HTD setting is an area still undergoing rapid
development. As a recent title of a review of DR methods by Fan & Lv (2010 [47]) suggests,
selectivity is needed for a review of DR itself.
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Univariable Feature Selection for Large Scale Dimension Reduction
Fan & Fan (2008 [46]) demonstrated that under certain conditions, a t test for each HTD
feature comparing differential expression between the non-responsive and responsive group can
be used to reduce dimensionality from ultrahigh to a moderate scale below or on the order of the
sample size n . This is a univariable Feature Selection (FS) method. The features could be ranked
and selected by p-value, false discovery rate (Benjamini & Hochberg, 1995 [8]), or the absolute
value of a t-statistic. The empirical Bayes t statistic (Smyth, 2004 [150] ) performed well across a
range of sample sizes (Jeffery, Higgins, & Culhane, 2006 [91]). Methods such as cross-validation
can be used to select a cut-off value to determine features for use in the prediction rule.
However, as stated in Chapter 1, a test comparing gene expression means for the two
classification groups may not prove useful in preserving features containing information
regarding treatment subset prediction. A more appropriate method used in simulations in Freidlin
et al. (2010 [55]) compares differential gene expression between enhanced and standard treatment
in the responsive group to differential expression in the non-responsive group. The equation is in
Chapter 1.
Dimension Reduction Impacts Classification Performance
In the Dudoit et al. (2002 [39]) study, DLDA performed well while FDA performed poorly
when the same number of selected features were used for each method. However FDA had error
rates comparable to DLDA when fewer features were selected in the DR step. The explanation
was that estimates of the pooled within-class covariance matrix for FDA become unstable when
the number of selected features is large. Since DLDA does not estimate the non-diagonal
elements, it eliminates variance associated with these parameter estimates in exchange for some
increase in bias.
Optimization of DR for classification depends on the classification method. The weighted
voting method used in Freidlin & Simon’s ASD model addresses this by including the DR tuning
parameter as one in a set of inter-related tuning parameters. In this way DR is embedded in the
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classification process. The set of tuning parameters chosen is the one which (using CV on the
training set only) minimizes the p-value in a treatment arm comparison of predicted sensitive
patients.
In selecting the list of plausible tuning parameters for this ASD implementation, it is
important to take into account factors that influence optimal cutpoint selection. These include the
sample size, the number of features, and the classification method. For example, if the
classification method is LDA, the number of selected features p * must be nD  2 or less (for
two classes). Moreover, it has been reported that LDA is unstable if nD is not at least 5 or 10
times p * (Jain & Chandrasekaran, 1982 [90]).
Methods used after Initial Large Scale Feature Selection
Though univariable FS is often preferred for an initial large scale screening, one drawback is
that it does not take into account correlation between features. Therefore it is possible that
features selected in this manner will be highly correlated.
Principal Components Analysis
One solution is to use a univariable FS method first to reduce features to some number p * ,
say less than or on the order of nD . Then principal components analysis (PCA) can be used to
extract a smaller number of uncorrelated features for use in treatment subset prediction in the
validation set. The method of Fisherfaces (Belhumeur, Hespanha, & Kriegman 1997 [7]) used a
similar approach.
PCA was originally proposed by Pearson over 100 years ago (1901 [124] ) and further
developed by Hotelling (1933 [83]). The principal components of p * features are the p *
orthogonal directions which maximize variance between the features. The first principal
component is the linear combination which maximizes the variance between the features, and the
second PC is the linear combination orthogonal to the first PC which maximizes the remaining
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variance, and so on. A number of principal components much smaller than m can usually be
found which explains most of the variance of the original features. However as pointed out by
Bickel & Li (2006 [5]), PCA breaks down when p  n : “…not only does the empirical
covariance matrix become singular for p  n , but , …, if

p
 c, 0  c  , the empirical
n

eigenvectors and eigenvalues are grossly inconsistent in terms of estimating the corresponding
population quantities.” Therefore PCA may not be an appropriate choice for an initial screening
when p  n . To address this issue, penalized methods such as sparse principal components (Zou,
Hastie, & Tibshirani, 2006 [185]) have been developed.
One difference between PCA and other DR methods is that PCA does not make use of
association between explanatory and response variables. The next method is one way of
addressing this issue.
Partial Least Squares
Partial least squares (PLS) “seeks directions that have high variance and have high correlation
with the response” (Hastie, Tibshirani, & Friedman, 2009 [75]). It was proposed by Wold in the
1960’s as an application for chemometrics for regression and DR (Geladi & Kowalski, 1986
[63]). Boulesteix (2007 [13]) compared applications of PLS in HTD. Nguyen & Rocke (2002
[118]) applied PLS to cancer classification. There are similar shortcomings in p  n problems
for PLS as for PCA, and penalized methods such as Sparse PLS (Chun & Keleş, 2010 [27]) have
been developed to help address this issue.
L1 and L2 Regularization Methods
There are other methods that could be used in this second step as well. For example L1R
methods constrain the sum of the absolute value of the coefficients to be a constant. This results
in shrinkage of regression coefficients and selection of at most n features depending on the
magnitude of the penalty term(s). This enables some L1R methods to be used in a first step DR as
well. Methods using L2R constrain the sum of the squares of the coefficients to be a constant
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value. This has the effect of shrinking coefficients towards a constant value without setting them
equal to that constant. In so doing degradation due to correlation is reduced. One example is the
L2R logistic regression for gene-gene and gene-environment interactions introduced by Park &
Hastie (2008 [120]). This method allows categorical factors such as treatment to be included in
interactions. Higher order gene-gene or gene-treatment interactions can be included. The
Adaptive LASSO (Zou, 2006 [184]) allows different penalty terms for each covariate. The elastic
net (Zou & Hastie, 2005 [183]) is a mixture of L1R and L2R and encourages strongly correlated
features to enter or leave the model together. The Group LASSO enables penalty terms to be
selected differently for different features, or for selected groups of features (Yuan & Lin, 2006
[178]). Selection of groups makes it possible to select, for example, genes involved in a biological
pathway. Jacob, Obozinski, & Vert (2009 [89]) extend Group LASSO to allow for overlap, as
might happen with genes in more than one biological pathways. Table 6 provides more
information on DR methods including software implementations.
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Table 6: Parametric DR methods and software implementations.
Method
PCA

Description

R Packages

SAS Software
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Principal components analysis – extracts a smaller
pls
Proc princomp, proc factor
number of uncorrelated features from a larger set of
possibly highly correlated ones. Breaks down in
p>>n situations.
SPCA
Modification to PCA which enables use in p>>n
pcaPP, PMA, elasticnet
*
data.
PLS
Partial least squares – like PCA, but also takes into
pls, caret
Proc pls
account association between features and response
variable (and therefore can also be used as
classification method). Breaks down in p>>n
situations.
SPLS
Modification to PLS that enables use in p>>n
spls
*
situations.
L1R (LASSO)
Constrains sum of absolute value of coefficients to
penalized, glmpath,
*
be a constant depending on penalty term. Shrinks
LiblineaR, elasticnet,
parameter estimates towards 0, allowing some to be lassoshooting
equal to 0; selects at most n features out of p.
Adaptive LASSO
Allows different penalty terms for each feature.
lqa, parcor, lars
*
Group LASSO
Allows penalty terms to be different for each feature grplasso, grpreg, SGL,
or for selected groups of features. Has been
stan𝑑𝐺𝐿, gglasso
extended to account for overlap (Jacob, Obozinski
and Vert, 2009).
L2R (Ridge
Constrains sum of the squares of parameter
LiblineaR, glmnet, lrm,
*
Regression)
estimates to be a constant, depending on penalty
penalized
term. Shrinks parameter estimates towards a
common value or towards 0 without eliminating any
of them. Can be used to stabilize covariance
matrices. Shrinks coefficients of correlated
predictors towards a common value. Ideal if there
are many predictors all with non-zero coefficients.
Combined L1R and
Constrains parameter estimates to be a sum of both
elasticnet, glmnet
*
L2R
the L1 and L2 constraints; also see Park and Hastie
2008.
*For SAS code on penalized/regularized methods, one can search sites such as http://www.sas-programming.com/2010/09/regularized-discriminant-analysis.html
and http://sasdiehard.blogspot.com/2011/03/fitting-logistic-regression-in-data.html for guidance.

4. Parametric Classification Models and Rules
Fisher’s Discriminant Analysis
Fisher’s idea was to find the compound distance which is the linear combination of
*
covariates, say zi*  1 zi1 ,...,  p* zip* (or zi  λ'zi , where λ and zi are the corresponding p* -

length vectors), which maximizes the between-class distance with respect to the within-class
variance. The between-class distance is

ˆ d*  ˆ1*  ˆ 0*  λ'  ˆ1  ˆ 0  ,
where ˆ g {ˆ 0 , ˆ1} denotes the p*- length vectors of class specific feature means estimated
*
*
from the training set; and where p * is the number of selected features. Note that ˆ1 , ˆ 0 , and

ˆ d* are scalars. The vector which maximizes the compound distance between classes ˆ d* with
respect to its pooled within-class variance can be found by differentiating and setting equal to 0
*2
*
the quantity ˆ d / s with respect to λ , where the scalar s*  λ'SSλ , and SS is the pooled within-

class sum of squares matrix for the original covariates. This leads to a system of p * linear
equations, where p*  nD  2 is the number of selected features. The solution is:

  SS 1  ˆ1  ˆ 0  .
In the case of equal class sample sizes, a classification decision can be based on which class
the compound distance for the subject is closest to:

 z *  ˆ *
gˆ i  arg min g  i * g
 ˆ






2


 , where ˆ g* {ˆ 0* , ˆ1*} are class specific means and ˆ * is the



pooled within-class standard deviation of the compound measures estimated on the training set.
Figure 6 gives a graphical depiction using the square-root of the squared distance above.
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Alternatively, a cut-off point can be determined using CV. For example,
2
2


 zi*  ˆ 0*   zi*  ˆ1*  


.
gˆ i  I  


C
 
 
*
*
ˆ
ˆ













Figure 6: Use of compound measure in FDA to allocate new subjects;

̂0*

and

̂1*

are the average of the

compound measures over all the subjects for class g=0 and g=1 on the training set; ̂ *2 is the within-class
pooled variance of the compound measure, also calculated from the training set; ˆ 0

*

the standardized class compound measures, and

ˆ d* / ˆ *  ˆ1* / ˆ *  ˆ 0* / ˆ *

/ ˆ * and ˆ1* / ˆ * are

is the difference between

these two class compound measures. The standardized compound measure for each subject i in the
validation set is

zi* / ˆ * . Predicted class gˆ i is determined by which standardized class compound measure,

ˆ g* / ˆ * , the standardized compound measure zi* / ˆ * is closest to in terms of the standardized compound

z
distance ,

*
i

 ˆ g* 

ˆ *2

2

, or,equivalently, to its square root. The cut-off for class membership is shown by

the dashed line half way in between the two classes (assuming equal sample sizes for classes). In this case,
if

z

*
i

 ˆ 0* 

ˆ

*2

2



ˆ d
, then gˆ i  0. Otherwise gˆ i  1.
2ˆ *
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Since no distributional assumptions are used in the derivation of the compound measure or
distance, authors such as Rencher (1991 [131]) classified FDA as nonparametric or distributionfree. Moreover Ripley (1996 [134] ) pointed out that “a t-distribution with a moderate number of
degrees of freedom is often regarded as a better fit” than a normal distribution. This robust
method is included in the R functions lda in package MASS (Venables & Ripley, 2002 [165]).
The Likelihood Ratio and Classification
Let Z denote the n by p gene expression profile matrix (the matrix over all features, and over
both the training and the validation set) , and let Z g denote the matrix of rows of Z consisting of

i 1,..., n such that gi  g. Suppose Z g follows a multivariate distribution with parameter
vector θ  θg . Each subject belongs to one and only one of G classes, but class membership for
subjects in the validation set is not known. In the special case where G  2 , then an LRT can be
used to assign subject i to one of the two classes. The hypotheses are:

H1 : g  1
H 0 : g  0.
The LR for the ith subject is then equal to the ratio of the product of the prior class
probabilities  g and class-dependent densities f (zi | θ  θg ) where here zi is the p-length gene
expression profile vector for subject i:

LRi 

Pr( g  1, zi ) Pr( g  1) Pr(zi | g  1) 1 f (zi | θ  θ1 )


, or LLRi  log( LRi ).
Pr( g  0, zi ) Pr( g  0) Pr(zi | g  0)  0 f (zi | θ  θ0 )

Note that this rule assumes knowledge of the true underlying class distributions. In this
unusual scenario, no model building on a training set is necessary. The classification rule can then
be expressed as gˆ i  I ( LLRi  0), where g {0,1}. Now if Z follows a multivariate normal
distribution, then, assuming a common covariance matrix Σ for the two classes:
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 1

exp   (zi  μ1 ) ' Σ 1 (zi  μ1 )  

   f (zi | μ1 , Σ )   1  
 2
 ,
LRi   1 
  

  0  f (zi | μ0 , Σ )   0   exp   1 (z  μ ) ' Σ 1 (z  μ )  
0
i
0 
 2 i

 
where  g is the p-length vector of true means for the columns of Z g . Extension to {x i , zi } is
straightforward.
The log likelihood ratio is:

   1
1

LLRi  log  1     zi  μ1  ' Σ 1  zi  μ1    zi  μ0  ' Σ 1  zi  μ0   .
2

 0   2
Note that

 z  μ  ' Σ  z  μ  is the Mahalanobis distance.
1

i

g

i

g

Now, if the true parameter values are not known, then it is necessary to estimate them from a
training set where class membership is known. Substituting ML estimates for true parameter
values:

 ˆ   1
1

LLRi  log  1     zi  μˆ 1  ' S 1  zi  μˆ 1    zi  μˆ 0  ' S 1  zi  μˆ 0  ,
2

 ˆ0   2
where S is the pooled within-class sample covariance matrix from the training set, and μˆ g is the
p*- length vector of ML estimates from the training set for  g . Here LLRi for subject i in the
validation set is used as the classification distance in place of LLRi since true parameter estimates
are not known. Note that when the true parameter values are known, there are no restrictions on
the number of features that can be used. However the true values are almost always not known. In
this case the number of selected features p* must be less than or equal to nD  2. The
classification rule is then: gˆ i  I ( LLRi  C ), where g {0,1}. Note that a cut-off C may be
used in place of 0 since there is no longer complete knowledge of the true underlying
distributions of Z g . The cut-off may be chosen using CV.
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Numeric Example
Take μˆ 0 '  0,1 , μˆ 1 '  1, 2 , S 

2 1
, equal prior class probabilities, and z i '  2, 2 . Then
1 2

LLRi  log(1)  (1/ 2)(2 / 3)  (1/ 2)(2)  0  2 / 3  2 / 3. Then, if
C  0, gˆ i  I (2 / 3  0)  1.
Relationship Between Linear Discriminant Analysis and Fisher’s Discriminant Analysis
The distance

 Zi  μˆ 0  S 1  Zi  μˆ 0  is a standardized version of Fisher’s compound
'

distance DCi and therefore LDA results in the same classification rule as FDA when ML
estimates are substituted for true values.
Diagonal Linear Discriminant Analysis
For DLDA, and substituting ML estimates for true parameter values, the equation further
reduces to:

 ˆ   1 p*
1 p*

LLRi  log  1      k 1 ( zik  ˆ1k )2 / ˆ k 2   k 1 ( zik  ˆ 0 k )2 / ˆ k 2  ,
2

 ˆ0   2
where ˆ k is the estimate (from the training set) for the pooled within-class variance for the
2

kth selected gene, and ˆ gk is the kth element of vector μˆ g . For DLDA, it is no longer necessary
that p * be less than or equal to nD  2 , since means and variances can be estimated separately
for each gene; however performance will still degrade unless p * is much less than nD .
The classification rule is the same as before – i.e. gˆ i  I ( LLRi  C ), where g {0,1}. For
a weighted voting method (Breiman, 1996 [16]), the summation sign would be eliminated and
separate models would be used for each selected feature. A cut-off can be chosen for the

LLRik ' s using nested CV, and the subject assigned to class g  1 if the number of genes having
an LLRik exceeding this tuning parameter, say R, is equal to or greater than the value of another
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tuning parameter, say H, also chosen using nested CV. This can be expressed as

  p*


gˆ i  I   I ( LLRik  R   H  .

 k 1

Likelihood Ratio Test and Misclassification Costs
Different misclassification costs for each class c(1  g , g )  c( gˆ  1  g , g ), g {0,1} can
also be included in the LRT. In this case the classification rule is



 c(0,1) f (zi | θ  θ1 )
gˆ i  I  log 1
 0  . This is the expected cost of misclassification (ECM)
 0c(1, 0) f (zi | θ  θ0 )


rule (Johnson & Wichern, 2007 [92]). True parameters can be replaced with their maximum
likelihood estimates as before. Note that, though a method such as CV could still be used here to
assign subjects, care is needed to assign appropriate weights to account for misclassification costs
and prior population probabilities. The distance used to make a classification decision in this case

 ˆ1c(0,1) f (zi | θ  θˆ1 ) 
 ˆ c(1, 0) f (z | θ  θˆ )  . For simplicity, this distance will also be referred to as an
0 
i
 0

is then log 

LLR in this work.
Numeric Example
Take previous values for μˆ g and zi , and take Σ = S in the previous example: with

c  0,1
ˆ
 2, and 1 =1, then LLRi  log(1*2*2 / 3)  0.288, and, if C is chosen as 0,
c 1, 0 
ˆ 0
gˆ i  I (0.288  0)  1.

A Note on Diagonal Linear Discriminant Analysis
The naïve Bayes DLDA, which compared favorably to methods such as Boosting and
Random Forests in Dudoit et al.’s 2002 study [39], sets the non-diagonal elements of the withinclass covariance matrix to 0, and therefore ignores correlation between features. Naïve Bayes
methods have been observed to work well in many situations despite the fact that the assumption
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is not generally true (Bickel & Levina, 2004 [9], Hastie et al., 2009 [75]). There is a trade-off
between bias reduction that results from estimating more covariance terms, and the increased
variance resulting from these estimates. In many situations the increased variance outweighs the
benefits of bias reduction.
Diagonal Linear Discriminant Analysis and Nearest Shrunken Centroids
The NSC method is a penalized form of DLDA proposed by Tibshirani, Hastie, Narasimhan,
& Chu (2002 [160]). It includes use of a tuning parameter which has the effect of shrinking
distance of genes from class centroid ( ˆ gk ) to overall centroid ( ˆ k ). Genes which have a
shrunken distance of zero for all classes are effectively filtered out of the classifier. In this way
DR is naturally integrated into the classification process. The tuning parameter is selected based
on nested CV. Increasing the tuning parameter results in fewer selected genes. It was found that
both training error and prediction error were minimized with a tuning parameter near 4.34. Guo,
Hastie, & Tibshirani (2007 [68]) introduced a related method called shrunken centroids RDA
(SCRDA).
Modified Linear Discriminant Analysis
MLDA (Ledoit & Wolfe, 2004 [99]) reduces bias and improves stability of the LDA
covariance matrix by shrinking the sample eigenvalues towards a common mean. Table 7
provides information on parametric classification methods, including regularized methods and
software implementations.
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Table 7: Some parametric classification methods and software implementations.
Method
Description
R Software
LCA

Classification using logistic regression.

Penalized LCA

Classification using penalized logistic
regression (L1, L2, or both).

FDA/LDA

QDA
DLDA
QLDA
Linear
Regression
Classification

RDA

PDA
Penalized
DLDA
Penalized
DQDA
MLDA
CS
Weighted
Voting

Classification method maximizing
between-class squared distance w.r.t.
within-class squared distance. Assumes
common within-class covariance matrix.
Same as FDA, except allows within-class
covariance matrix to be different for each
class.
Uses diagonal within class covariance
matrix (non-diagonal elements set equal to
0).
Same as DLDA, but allows unequal
diagonal elements for each class.
Formulates FDA as regression – gives
same classification rules when using
appropriate numeric values for classes.
Shrinks unequal within-class covariance
matrices assumed in QDA towards equal
covariance matrices assumed in FDA; also
shrinks individual class covariance
matrices towards identity matrix
multiplied by average of eigenvalues;
amount of shrinkage in each direction
determined by cross validation.
Formulates FDA as a regression problem.
Then penalized methods for regression
can be used.
Uses diagonal within class covariance
matrix, and shrinks diagonal elements
towards common value or towards 0.
DQDA with diagonal elements shrunk
toward 0 smoothed.
Shrink sample eigenvalues towards
common mean using closed form solution.
Non-diagonal elements of covariance
matrix assumed equal.
Prediction using single gene models.

glm(base), lrm(rms),
polr(MASS)
logistf(logistf),
penalized(penalized), glmnet,
elasticnet, also see Park and
Hastie, 2008

SAS Software
Proc logistic,
Enterprise Miner
Proc logistic

lda(MASS)

Proc discrim

qda(MASS)

Proc discrim

diagDA(sfsmisc)
stat.diag.da(WGCNA)

Proc discrim

diagDA(sfsmisc)

Proc discrim

Any package for linear
regression

Any procedure
for linear
regression

rda(klaR), rda(rda)

Proc discrim
with sample code

mda(mda), pdmclass
penalizedLDA
(penalizedLDA), pamr
sdqda(sparsediscrim)
Ledoit & Wolfe 2004,
Xu,Brock, & Parrish 2009
Not aware of any
implementation
votingLinearPredictor(WGCNA)

Linear Regression and Classification
Bishop (2006 [10]) and Duda, Hart, & Stork (2001 [38]) showed that linear regression, with
appropriately chosen cutoffs for the two classes, has the same classification rule as FDA and
LDA. This was also implied in Fisher’s 1936 work. Robust regression methods such as Median
Absolute Deviation (MAD) or M-regression could also be used, though in these cases the
classification rule will not be the same as for FDA or LDA using ML estimates.
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If using the linear regression form of LDA, the class variable G is used as the response
variable, and gene expression Z and other covariates are used as explanatory variables. The
classification rule for subject i in the validation set is is

gˆ i  sign( yˆi  ˆ0  ˆ1 xi1  ˆ2 xi 2  ...  ˆm xim  ...  ˆ zil ), where gˆ i {1,1}. It follows that
the linear regression distance used for classification is yˆ i . Interaction terms can also be included.
The coefficients are estimated from the training set, using response variable y {1,1} for class

g {1,1}, assuming equal sample sizes. The response variable can also be adjusted for
unequal sample sizes. See Bishop (2006 [10]) or Fisher (1936 [48]) for details. Nested CV can
also be used to determine an appropriate cut-off C; i.e. gˆ i  sign( yˆi  C ).
Numeric Example
Using nested CV, the tuning parameter set selects three genes on the validation set. A multigene linear regression is used on the validation set. Sample size for the two classes are equal.
Estimated parameters from the training set are ˆ0  0.4, ˆ1  0.5, ˆ2  0.4, and ˆ3  1.2.
Gene expression for the three genes for subject i in the validation set are

zi1  1.1, zi 2  0.8, and zi 3  1.3. Taking C  0, gˆ i  sign(0.4  ...  1.2*1.3)  1.
Linear Regression Classification with a Continuous Response as Outcome Variable
In some settings a continuous variable can be used as the outcome variable. This is more
natural for methods such as linear regression. This approach was used in Rai, Cambon, Pan,
Gargett & Chaires (2013 [129]) in an application involving differential scanning calorimetry
plasma thermogram analysis. Residuals were used as a distance measure. Two models were
compared, one assuming gi  0 and one assuming gi  1 for each subject i in the validation set.
Parameters for the models were estimated from the training set, and feature values xik were taken
from subjects in the validation set. Subjects in the validation set were allocated to the class whose
model had the smallest residual distance. In this case the residual distance was the average
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number of residuals whose absolute value exceeded a specified quantile: i.e.:

gˆ i  sign  p0  p1 , where pg is the average proportion of residuals for subject i with absolute
value exceeding a specified quantile, under the model assuming gi  g. The specified quantile
can be estimated from the training set. The distance used for classification in this method is then

p0  p1.
Another advantage of regression methods for classification is the wealth of related tools that
have been developed. Splines (Friedman, 1991 [59]), additive models (Hastie & Tibshirani, 1987
[73]), regularized methods and quantile regression (Koenker & Bassett, 1978 [95]) are some of
many examples. Importantly for treatment subset prediction, one can naturally include treatment
interactions in regression models to make a classification decision. The classification method
outlined next, LCA, is a regression method and can also make use of these approaches.
Logistic Classification
Many works such as Press & Wilson (1978 [127]) have compared LCA and LDA. It has been
found that their performance is surprisingly similar under many scenarios. LDA will perform
better when the normality assumption is approximately true (or when suitable transformations can
be applied which results result in this assumption being approximately true), and LCA will have
superior performance when this assumption is severely violated (Hastie et al., 2009 [75]).
Logistic regression takes the form

logit(y|xi , zi )  0  1 xi1  2 xi 2  ...m xim   1 zi1  zi , where
 Pr (y =1|x i ,zi ) 
y {0,1}, and logit(pi )= log 
 . Logistic regression is in the class of
 1- Pr (y =1|x i ,zi ) 
generalized linear models, and the logit is the link function. Covariates can be continuous or
categorical, and this allows clinical as well as genomic features to be included in the model
simultaneously. Logistic classification is simply logistic regression used for classification. For
LCA, the categorical response is the class variable g. Appropriate cut-offs can be used to
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determine classification. For example, gˆ i  I (logit( pi )  C ), gi {0,1}, where the constant C
can be chosen as 0 or selected through nested CV. The distance for LCA is then the logit. Since
the logit is the log of the odds, it is then natural to use the treatment arm OR to evaluate the
difference in this distance between treatment arms for treatment subset prediction. This is the
approach taken in Freidlin & Simon’s version of ASD.
Single-Gene Logistic Classification-Treatment Subset Prediction
This version of ASD employs single gene logistic models to predict a subset of patients more
likely to respond to treatment. In that method the treatment arm OR is used as a distance in a
weighted voting procedure to determine sensitivity to treatment. The single gene logistic model
for subject i and gene k is: logit( pi | zik , ti )    k ti   k ti zik , where ti is the treatment arm
indicator for subject i in the validation set, zik is gene expression for gene k and subject i, and

k and  ik are coefficients for treatment and treatment-gene interaction respectively. Main
effects for gene expression are also included in the implementation of Scher, Nasso, Rubin &
Simon (2011 [144]), ]), though the model is different from the one shown here. When patient
sensitivity prediction for the final validation set is undertaken, outcome results for the training set
are known, as are gene expression results zik for subject i in the validation set, even though
outcome results g i are not. Gene-weighted voting estimates for sensitivity to treatment for subject

i can then be obtained using the treatment arm OR. Subject i has not necessarily been assigned
to a treatment arm, however the treatment arm OR compares both treatment assignment
scenarios: i.e. ORik  e

ˆ ˆk ˆk zik

ˆ

/ eˆ  ek ˆk zik using the parameter estimates on the training set

and gene expression zik from the validation set. A value of ORik exceeding R results in a vote
by gene k for subject i being sensitive to treatment. This can be expressed as:
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  p*


Sni  I   I (ORik  R)   H  ; where Sn is an indicator variable for subject sensitivity, and

  k 1


k  1,..., p * are the genes selected from the DR step.
The assumed model for the weighted voting method is that some but not all sensitive genes
for a subject sensitive to treatment are overexpressed. The weighted voting tuning parameters
determine the fraction of genes and the amount of overexpression in order for the subject to be
predicted sensitive. However a simplified approach may be to eliminate tuning parameter H by
calculating a summary score over all the selected genes for a subject. Figure 1 is a detailed
flowchart of the ASD method.
The assumed model for the weighted voting method is that some but not all sensitive genes
for a subject sensitive to treatment are overexpressed. The weighted voting tuning parameters
determine the fraction of genes and the amount of overexpression in order for the subject to be
predicted sensitive. However a simplified approach may be to eliminate tuning parameter H by
calculating a summary score over all the selected genes for a subject. Figure 1 is a detailed
flowchart of the ASD method.
Multivariable Logistic Classification
The LCA method used as an example in Freidlin & Simon’s work was a single gene logistic
model. However multivariable multi-gene models can also be used for ASD, as in Scher et al.
(2011 [144]); note that in this work a multivariable proportional hazards model was used. A
multivariable LCA approach was not used in the Dudoit et al. 2002 work (which did not involve
an ASD implementation) due to issues of class separation. In that case ML estimates do not
converge. Use of a penalized ML method (Heinze & Schemper, 2002 [76]) is one way to address
this, and this option is readily available in R or SAS software. An advantage of the L2R
multivariable logistic method of Park & Hastie (2008 [120]) is that it enables incorporation of
higher order gene-gene interactions. This method might therefore be preferred to LDA when it is
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felt that higher-order interactions are not ignorable. Note that since higher order gene-gene
interactions are involved, a prior DR method may still be needed in a typical HTD setting.
5. Discussion and Conclusions
Methods such as LDA and LCA are constructed using distance metrics. The example of the
ASD method in Freidlin & Simon’s work used the treatment arm OR as a distance in a weighted
voting method to determine sensitivity to treatment. Other distance measures and other methods
can be incorporated into treatment subset prediction. The LLR measures the distance of a subject
from the border of the two classes. An LLR of 0 indicates the borderline between two classes.
The sign and magnitude can be used to develop criteria for voting or allocating a subject to a
given class. Sensitive subjects can then be predicted using methods which incorporate this
distance. Using single gene densities, the equation for the difference in the LLRik between the
two treatment arms for gene k and subject i in the validation set is:

DLLRik  LLRik ,t 1  LLRik ,t 0  log

ˆ11 f ( zik
ˆ01 f ( zik

| ˆ11k )
ˆ f ( zik
 log 10
| ˆ )
ˆ f ( z
01k

00

ik

| ˆ10 k )
,
| ˆ )
00 k

where f ( zik | ˆgtk ) is the density for gene k with estimated parameter vector ˆgtk , and evaluated
at zik . The parameter vector ˆgtk , is conditional on class g, treatment arm t, and gene expression
for gene k. Estimated prior class probabilities ˆ gt are also conditional on class g and treatment
arm assignment t, but not on gene k. The estimates for parameters and prior class probabilities are
derived from the training set.
Numeric Example
From training set control arm there are 25 subjects who responded and 75 subjects who did
not respond to treatment. On the training set treatment arm, 40 patients responded and 60 did not.
Then ˆ10 / ˆ00  0.333 and ˆ11 / ˆ01  0.667. Gene expression density parameters for gene k
are estimated from the training set (after appropriate gene expression normalization). If Gaussian
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densities are used, then densities for gene k conditional on class and treatment arm and evaluated
2
at zik are f ( zik | ˆ gtk , ˆ gtk ). Estimates of parameters conditional on response status g and

treatment arm t can be derived from the training set used to estimate corresponding densities.
Suppose for selected gene k we have

(ˆ gtk , ˆ 2gtk ) (0,0.04),(0.1,0.04),(0.1,0.04),(0.6,0.16) for

 g , t   0,0 , 1,0  ,  0,1 , 1,1; gene expression

zik  0.9. Then

f ( zik | ˆ11k , ˆ112 k ) f (0.9 | 0.6, 0.16)

=1125,
f ( zik | ˆ 01k , ˆ 012 k ) f (0.9 | 0.1, 0.04)
f ( zik | ˆ10 k , ˆ102 k ) f (0.9 | 0.1, 0.04)
and

 8.373.
f ( zik | ˆ 00 k , ˆ 002 k )
f (0.9 | 0, 0.04)
Therfore DLLRik  log(1125*2 / 3)  log(8.373*1/ 3)  5.59.
Then, if 5.59 > R, gene k would cast a vote for sensitivity for patient i in the validation set.
The parameter set { , R, H } could, as before, be selected using nested CV or the nested bootstrap
from a list of prospectively chosen turning parameter sets.
Alternatives to Weighted Voting
Distances such as these can be used in an ASD treatment subset prediction method
incorporating tuning parameters very similar to  , R, and H . Alternatively, if the weighted
voting assumption that some but not all selected genes are overexpressed is deemed not
appropriate, tuning parameter H can be eliminated, and the cut-off R can be used on the average

DLLRik of the selected genes for a subject. If the naïve Bayes assumption is severely violated, a
multivariable method such as LDA could be used to calculate DLLRi over all the selected
features for subject i in the validation set. This equation then becomes:

DLLRi  log

ˆ11 f (zi | ˆ11, S.1 )
ˆ f (zi | ˆ10, S.0 )
 log 10
,
ˆ01 f (zi | ˆ 01, S.1 )
ˆ00 f (zi | ˆ 00, S.0 )

67

where ˆ gt indicates estimated prior class probabilities for class g and treatment arm t, ˆ gt is the
estimated vector of means for selected features conditional on class g and treatment arm t, S.t
denotes the pooled sample covariance matrix for treatment arm t, and zi is the vector of selected
features for subject i in the validation set. As before, all estimates are from the training set.
Tuning parameter H is also eliminated in this approach. Values of DLLRi near 0 are indicative
of no treatment interaction for subject i .
The Posterior Odds Ratio and Treatment Subset Prediction
It may also be more intuitive to use the estimated or plug-in posterior OR:

ORi post 

Pr post ,i1t 

Pr post ,i11 / (1  Pr post ,i11 )
Pr post ,i10 / (1  Pr post ,i10 )

ˆ1t f (zi | ˆ1t )

1

 ˆ
g 0

gt

f (zi | ˆgt )

, where the estimated posterior probability

.

Also single gene posterior odds ratios ORik post can also be used in the same way as the
treatment ORik in an ASD method. That is, tuning parameter R is used to select a cutoff for the

ORik post , and parameter H selects the number of genes needed to exceed R in order for the
subject to be predicted sensitive. Parametric methods using the above approaches are described
below.
Numeric Example for Single-Gene Posterior Odds Ratio
Using the previous numeric example,

ˆ11 f ( zik | ˆ11k , ˆ112 k )
 0.9987 and
ˆ01 f ( zik | ˆ 01k , ˆ 012 k )  ˆ11 f ( zik | ˆ11k , ˆ112 k )
ˆ10 f ( zik | ˆ10 k , ˆ102 k )
 0.7362; then
ˆ00 f ( zik | ˆ 00 k , ˆ 002 k )  ˆ10 f ( zik | ˆ10 k , ˆ102 k )
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ORik post 

0.9987 / (1  0.9987)
 89.6, or log(ORik )  4.50.
0.7362 / (1  0.7362)

If ORik exceeds tuning parameter R (obtained through nested CV), then the gene k casts a
vote in favor sensitivity for subject i.
Linear Discriminant Analysis and Treatment Subset Prediction
The compound distance measure derived in FDA measures how close a subject is to one class
or the other. This approach also has the same classification rule as LDA when ML estimates are
substituted for true values. For classification purposes, a cutpoint is usually determined based on
CV and the subject is allocated based on this decision. However for treatment subset prediction,
the difference in this distance across treatment arms can be evaluated. The equation becomes

 1

 1

 10 exp  mi10 
 2
  log
 2
,
DLLRi  log
1
1




 01 exp  mi 01 
 00 exp  mi 00 
2
2





 11 exp  mi11 

where migt is the square of the Mahalanobis distance; migt  (zi  μgt )'Σ.t 1 (zi  μgt ) for subject

i in the validation set, and using parameters for class g , and treatment arm t. This necessitates
computation of m for each treatment arm as well as each class. A common within-class
covariance matrix is assumed for a given treatment arm for LDA. However the covariance matrix
might be expected to vary across the two treatment arms. In this case a different within-class
pooled covariance matrix could be used across treatment arms ( Σ.t ), as shown in the equation
above. As before, estimates usually need to be used in place of unknown true parameter values,
and prior class probabilities and densities are estimated from the training data. Further
improvements can often be obtained by using L2R versions for the covariance matrix such as
those described in Ledoit & Wolfe (2004 [99]) and implemented in Xu et al. (2009 [177]), and
L1R or L2R versions of LDA, which also have an impact on the covariance matrix. Extensions of
the above method to DLDA, weighted voting, and posterior OR’s are straightforward.
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For QDA and DQDA (Diagonal QDA), to account for the different covariance matrices

 1
 2




between classes, the quantities exp  migt  in the above equation must be replaced with

 2 

1
p*/2

1/2

| Σ gt |

 1

exp  (zi  μgt )'Σ gt 1 (zi  μgt )   .
 2


QDA is more sensitive to departures from normality than LDA, and it is to be expected that
instability of the covariance matrix will be even more of an issue with QDA than with LDA, since
separate covariance matrices are estimated for each class. There are L2R versions of QDA and
DQDA (Table 3) that help address these issues.
For treatment subset prediction in an application involving HTD, a separate DR step is
needed before application of unpenalized versions of LDA or QDA. For guidance see Fan & Lv
(2010 [16]). For the unpenalized versions of LDA, DR would need to reduce the number of
selected feature to be less than treatment arm-specific sample sizes on training set. Specifically:

p*  min  nD,t 1  2, nD,t 0  2  . Further reduction would be needed, as described earlier, to
avoid instability of the covariance matrix. The remaining features are then used to predict a subset
of sensitive patients. To select the tuning parameter to be used in the validation set for DLLRi , a
nested CV approach can be used on the training set only.
Linear Discriminant Analysis Regression and Treatment Subset Prediction
As stated earlier, linear regression, with appropriately chosen cutoffs for two classes, is
equivalent to LDA. However one advantage of using linear regression in place of LDA in an
ASD setting is that treatment-gene interactions can be naturally incorporated into the regression
model. For example, using an ASD approach similar to Freidlin & Simon:

E ( g )  0k  k ti   k t i zik , where g {1,1}. In place of the treatment arm OR in the LCA
approach to ASD, this equation has a treatment arm estimate ˆk  ˆk zik . Again, for unequal class
sizes, appropriate adjustments can easily be made to the outcome variable.
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The equivalence of linear regression to LDA extends to multivariable regression as well. In
that case treatment gene interaction terms and main effects would be needed for each (selected)
gene. Furthermore, taking advantage of the relationship between LDA and regression, use of
robust regression methods such as M-estimation (Venables & Ripley, 2002 [165]) and MAD
could be explored in a treatment subset method.
Use of Residuals and Treatment Subset Prediction
With many regression methods it is more natural to use a continuous variable as the response.
The approach used in Rai et al., (2013 [129]) described in Section 4 can be extended to treatment
subset prediction. The classification distance used in that method to classify a subject as diseased

( g  1) or disease free ( g  0) is ( pi 0  pi1 ) . A positive distance for subject i is more indicative
of disease, and a negative distance is more indicative of a disease-free status. To extend this
distance to treatment subset prediction, the models are built separately on both the training set
treatment arm and the training set control arm. The 95% quantiles are also determined from these
two arms. Then the difference in these distances between the two treatment arms is calculated:

( pi 01  pi11 )  ( pi 00  pi10 ), where pigt is the average number of residuals exceeding a specified
quantile under the model assuming g=g and t=t. In the differential scanning calorimetry setting,
there is one equation for each subject i , so a tuning parameter similar to R can be used as a cutoff to predict patient sensitivity to treatment, without additional need for tuning parameter H .
6. Challenges and Future Directions
It is known that no single classification method can be optimal for all situations (Wolpert,
1997 [176]), so it is advantageous to have different methods for different data structures. In
particular, the DR and classification method should be selected to be consistent with the goal of
the study and with the distribution of the features. For example, if the goal is treatment subset
prediction, then a DR method that selects features based only on treatment main effects is not
optimal. If the data is highly skewed and a transformation such as those found in Box & Cox
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(1964 [14]) or Parrish et al. (2009 [121]) cannot be found which results in features which are at
least approximately normal, then both a DR and classification method are needed which are
robust to departures from normality. For example the use of logistic regression for both DR and
classification might be considered in this case (though LDA or DLDA may still perform well
when the normality assumption is not severely violated). Table 8 provides some guidance
regarding selection of DR and classification methods for difference scenarios and situations.
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Table 8: Select parametric dimension reduction and classification methods – situation and
conditions.
Method
Situation
Condition
Dimension
Reduction
PLS, PCA
SPLS or SPCA
t test

ANOVA
Univariable logistic
regression
L1R methods
L2R Methods
Classification

Used in presence of high multicollinearity/correlation
between features such as in face recognition or
chemometrics. PLS can also be used as a classification
method.
Same as above.
Used to screen for treatment main effect, but not treatmentgene interactions; allows moderate deviation from normality
(conditional on class) possibly after appropriate
transformations; can allow for different variances between
classes.
Used to select features based on treatment-feature
interactions, or to select features based on more than two
groups/classes; assumes constant variance between
groups/classes.
Used to screen for main effects or treatment-feature
interactions; no requirement that features follow a specific
distribution.
Best applied when only small subset of a large number of
covariates/features is active.
Best used when there are a large subset of active
covariates/features –can be used to identify gene-treatment
interactions in presence of gene-gene interactions.

p*>nD, p*<nD
p>> nD
p>> nD

p>> nD

p>> nD
p*> nD, p>> nD
p*> nD

Best performance when deviation from multivariate
Recommend
normality not severe for selected features; assumes common
p*< nD /5
within class covariance matrix.
Robust to departures from distributional assumptions; often
Recommend
Multivariable LCA
used as standard.
p*< nD /5
Best performance when deviation from multivariate
normality not severe for selected features; assumes different
Recommend
QDA
covariance matrices between classes. Not robust when
p*< nD /5
assumptions are violated.
Assumes independence between features, but naïve Bayes
methods can work well with some correlation; assumes
DLDA
p*< nD
constant variance between classes for each feature. Allows
moderate deviation from normality
Assumes independence between features, but naïve Bayes
methods can work well with some correlation; assumes
DQDA
p*< nD
different variance between classes for each feature. Allows
moderate deviation from normality.
Best used when there are a large number of active features
MLDA
and non-diagonal elements of covariance matrix are not
p*> nD
ignorable (naïve Bayes approach no longer optimal).
Single gene models “vote” to predict class; in class of naïve
Weighted voting
Bayes method; can tolerate some correlation between
p*< nD
features (as high as 0.6 in Freidlin & Simon 2005 work).
p - total number of features; p* - number of selected features; nD sample size of training set; note - DR methods such as
FDA or linear
regression

PLS, logistic regression, and L1R/L2R methods can also be used for classification.
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There are many challenges remaining:
1. How does one choose between different methods? There are established tests for normality,
but some methods such as LDA may still perform well when this assumption is not severely
violated. Also transformations may be used to make expression values less skewed and/or
more approximately normally distributed. Are ensemble classifiers that incorporate several
different classification methods an alternative approach?
2. The assumption inherent in weighted voting is that some but not all selected features in a
signature are overexpressed. When is this assumption appropriate? If not appropriate,
simplification can be achieved by eliminating parameter H and calculating an average score
over all selected features. Further, when are multivariable models preferred over single
feature models?
3. Further work needs to be done on evaluating methods which incorporate higher-order genegene and gene-treatment interactions for treatment subset prediction.
4. Several works cite the importance of biological pathways in treatment subset prediction. How
can pathway analysis be incorporated more directly into treatment subset prediction. Do
treatment interactions occur at the gene level or at the pathway level? How can treatment
subset prediction be incorporated into studies which include different types of genomic
information, such as miRNA’s, mRNA’s, and SNP’s.
5. The purpose of the ASD methods described in this work is not to establish a set of predictive
biomarkers but to predict sensitive patients. However the method will not work unless
predictive genes are selected, so there is information that could be used. Nested CV on the
training set can result in different genes being selected. At the same time, there is information
that could be used to help move the process forward, such as the frequency of genes selected
for each bootstrap or nested CV. Methods which mine ASD results to help establish
predictive biomarkers would seem useful.
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ESTIMATING DESIGN PARAMETERS IN THE PRESENCE OF GENE AND
GENE -TREATMENT INTERACTION
1. Introduction
The effect or association of specific genes or genomic signatures on response rates to types of
treatment are well documented. One example involves triple-negative breast cancer (TNBC),
which is breast cancer in absence of staining for the estrogen receptor (ER) progesterone receptor
(PR) and HER2 (Irvin & Carey, 2008 [87]). “Neoadjuvant chemotherapy studies have
consistently reported higher response rates in TNBC than non-TNBC … The pCR [pathologic
complete response] rate in the 23% of patients with TNBC was double that of the non-TNBC
subset” (Isakoff , 2010 [88]).
As well, treatments specific to melanoma and applicable to a subset of patients have more
recently been coming onto market. For example, subsequent to the findings in Viros et al. (2008
[166]), a treatment Vemurafenib, for a subset of patients having melanoma with BRAF V600e
mutations (Chapman et al., 2011 [24]) was approved by the FDA. In the year prior, Ipilimumab
was approved by the FDA for treatment of metastatic melanoma (Hodi et al., 2010 [79]). Saenger
& Wochok (2009 [139]) had previously shown that heterogeneity is present in patient response to
Ipilimumab. Methods are being developed for clinical studies which use genomic information to
find a subset of patients which respond differently to treatment. The Adaptive Signature Design
(ASD) in Freidlin & Simon (2005 [54]) is used to find a subset of patients responding differently
to treatment in phase III clinical studies in cases where a genomic signature has not yet been
developed.
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Purpose of Study
The ASD model consists of two tests- one to assess overall treatment effect, and another to
evaluate treatment effect restricted to a subset of patients prospectively predicted to be sensitive
to treatment. Type 1 error controlled by allocating it between these two tests. In this work a
method is given for calculating sample size of training set to attain a given power for the subset
test. This method takes into account gene overlap between classes.
Organization of Study
Section 2 covers notation and definitions. Section 3 outlines background for the adaptive
signature design. Section 4 describes an adaptive signature design similar to Freidlin and Simon.
Power for the Adaptive Signature Design is in Section 5, and limitations are in Section 6.
2. Notation and Definitions
The sample sizes of subjects for Stage 1 and Stage 2 are n1 and n2 respectively; the total
sample size is n  n1  n2 . Stage 1 serves as the training set where the prediction model is built
(using nested cross validation), and Stage 2 serve as the final validation set where patient
sensitivity is predicted.
A subject that is sensitive to treatment has a greater probability of response on the treatment
arm than on the control arm. Response-to-treatment status is denoted by random variable Y ,
which takes on values 0 for no response, and 1 for response to treatment. The probability that any
new subject accrued into the study is sensitive is pS , and pR is the probability of response
ST
given Si  s and Ti  t , where S {0,1} and T {0,1} are random variables for patient
sensitivity status and patient treatment arm status respectively. The number of evaluated genes is
p. Within these p genes it is assumed that there is a set of predictive genes which can be used to
predict sensitivity status of subjects. Without loss of generality, it is assumed that the first m
genes, k  1,..., m, are the predictive genes. The p-length vector of gene expression for subject i
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is denoted by random variable Z i , and the kth element of that vector (gene expression for the kth
gene for subject i) is Z ik . Fixed realization of these quantities are denoted by lower case letters.
3. Background for the Adaptive Signature Design
1) Gene expression profile of predictive genes k  1,..., m follows a multivariate normal
distribution which depends on sensitivity status of subject. The distribution of predictive
genes is multivariate normally distributed with mean vector μ1 and covariance matrix Σ1 for
sensitive patients, and mean vector μ 0 and covariance matrix Σ 0 for nonsensitive patients.
a. The sample size planning method proposed constrains these two covariance matrices
to be equal.
2) The distribution of nonpredictive genes k  m  1,..., p also follows a multivariate normal
distribution, but the means do not depend on sensitivity status- the distribution is the same for
all subjects.
3) The distribution of predictive genes is independent of treatment assignment; the results of the
assay are not used to assign subjects to a specific treatment arm:

Pr(Zik , Ti )  Pr(Zik ) Pr(Ti ), i, i  1,..., n; k  1,..., m.
4) The distribution of expression of predictive genes for sensitive patients is not independent of
response: Pr(Zik , Yi )  Pr(Zik ) Pr(Yi ); i s.t. si  1, k  1,..., m.
5) The distribution of expression of predictive genes for nonsensitive patients is independent of
response: Pr(Zik , Yi )  Pr( Zik ) Pr(Yi ); i s.t. si  0, k  1,..., m;
6) For the non-predictive genes, expression is independent of response; i.e.:

Pr(Zik , Yi )  Pr(Zik ) Pr(Yi ); i  1,..., n; k  m  1,..., p.
7) The nonpredictive genes are constrained to have the same mean regardless of sensitivity
status of a subject. In the ASD model proposed by Freidlin & Simon, they have the same
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mean as the predictive genes for non-sensitive subjects, but have different variance which is
2
denoted here by  ns : i.e.:

Zik ~ N (0 ,  ns 2 ), k , k  m  1,..., p.
8) There may also be positive correlation among predictive genes, and correlation among
nonpredictive genes.
4. An Adaptive Signature Design Model Similar to Freidlin and Simon
In the ASD model, parameters are estimated over gene expression for both sensitive and nonsensitive subjects. The purpose is to predict patient sensitivity, so patient sensitivity cannot be
treated as known in the model. Therefore the model parameters must be estimated on the training
set without regard to subject sensitivity status. However gene expression zik is known, and for
predictive genes k  1,..., m, zik is conditional on the unknown value of si . The model relating
expected value of gene expression for predictive genes E (Zik ), k  1,..., m , patient sensitivity
status and treatment arm status to response probability pRi can be written:

 pRi | Si , Ti
logit( pRSTi )  logit pR i | Si , Ti , E ( Zi )  log 
 1  pR | Si , Ti
i

m
(1  Si ){ 2 k E ( Zik | Si  0)  12 k Ti E ( Zik | Si  0)}
 
.
k 1   Si { 2 k E ( Z ik | Si  1)  12 k Ti E ( Z ik | Si  1)}







   0  1Ti



(4.1)

Now, if expected value of expression for predictive gene depends only on sensitivity status of
subject, (i.e.- E (Zik | Si  s)  sk ) then subscript i can be dropped since probability of response
no longer depends on i, and for a sensitive subject on the treatment arm:

logit( pR11 )  logit( pR | S  1, T  1)  0  1     2 j 1k  12 k 1k .
m

(4.2a)

k 1

For non-sensitive subjects on the treatment arm:
m

logit( pR01 )  logit( pR | S  0, T  1)  0  1   (  2 k 0 k  12 k 0 k ).
k 1
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(4.2b)

For a sensitive subject on the control arm:
m

logit( pR10 )  logit( pR | S  1, T  0)  0    2 k 1k .

(4.2c)

k 1

For a nonsensitive subject on the control arm:
m

logit( pR00 )  logit( pR | S  0, T  0)  0    2 k 0 k .

(4.2d)

k 1

where 1 is coefficient for the treatment main effect over all the subjects,  2k is the coefficient
for gene expression main effect for the kth predictive gene, and 12k is the treatment-expression
interaction effect for the kth predictive gene.
4.1 Predictive Value of Mean Expression
Note that this model assumes that it is the expected or mean value of predictive gene
expression for a subject that is predictive of probability of response, but not the variation around
the mean. The reasoning behind this is that short term variation in gene expression around the
mean can be due to technical variation and short term (e.g. day to day) biological variation, such
as variation due to instability in mRNA. These would not be expected to influence pR . (Over
time, mean expression may change, and this change may influence probability of response. This
situation is not considered in this work). However, even though in this model the assumption is
that it is the mean of expression values which are predictive, these values are not known in
practice, so the gene expressions zik are used in their place for prediction purposes. Sensitivity
status for a subject is also not known. The purpose of ASD is to predict sensitivity status. The
ASD model, using maximum likelihood estimates from the training set substituted for true
unknown parameter values, using selected genes in place of the true unknown predictive genes,
is:
m*





logit( pˆ Rti )  logit( pˆ R | ti , zik * )  ˆ0  ˆ1ti   ˆ2 k zik *  ti ˆ12 k zik * ,
k *1
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where k*  1,..., m * are the m* genes predicted to be sensitive (using the DR step), and where
information to predict si must be derived from the zik * expression values in place of the  sk , as
well as the estimated model coefficients, and their relationship with ti. The following observations
are made:
1) High overlap is obviously desired between the m* genes predicted to be sensitive, and the m
genes that are actually predictive. If there is no overlap, then the classification accuracy will
be no greater than that expected due to chance alone.
2) Subscript s is not used in estimated logit pˆ Rti . Even though expected values of gene
expressions for predictive genes are dependent on sensitivity status, gene expression values
are used regardless of sensitivity status, since sensitivity status is being predicted and is
unknown.
3) The assumption that probability of response is dependent only on treatment arm and
sensitivity status and not on subject is made for purposes of generalization for sample size
and power analysis. For example in the Dobbin & Simon work (2007 [36]), sample size
calculations for probability of correct classification ( PCC (n1 )) are based on a common
effect size for all predictive genes. The effect size is the difference between means of gene
expression for predictive genes for sensitive patients and means of gene expression for
nonsensitive patients, divided by the standard deviation. For purposes of sample size
calculation, Dobbin and Simon argue that the variance estimate used to calculate effect size
can be based on the 90 percentile of gene variances.
4) Even though the true logit does not depend on i, the estimated logit does depend on i, since
the realized gene expression values must be used in place of true expression means. In order
to predict sensitivity for subject i in the validation set one could use the treatment arm odds
ratio, as is done in F&S. Subject i has not necessarily been assigned to a treatment arm, but
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the treatment arm odds ratio is a measure of the difference in probability of response over the
two treatment arms, which in turn is a measure of sensitivity of the subject to treatment.
m*


ORi  exp logit(pˆ R1i )  logit(pˆ R0 i )   exp  ˆ1   ˆ12 k * zik*  .
k * 1



Simulations by the authors have also shown that single gene posterior odds ratios based on,
for example posterior odds ratios from parametric or nonparametric densities (Cambon,
Baumgartner, Brock, Cooper, & Rai 2015 [20]), hold up reasonably well to single gene logistic
models, even when model assumptions for LDA are violated.
4.2 Probability of Response
Now probability of response conditional on treatment arm and sensitivity status can be
expressed as: E (Y | S  s, T  t )  E (Yst )  pR st 



exp logit( pRst )





1  exp logit( pRst )



.

(4.3)

For example, for sensitive patients on the treatment arm, the probability of response is:

E (Y11 )  pR 11 



exp logit( pR11 )





1  exp logit( pR11 )



, and E (Y01 )  pR 01 



exp logit( pR01 )





1  exp logit( pR01 )



,

and similarly for E (Y10 ) and E (Y00 ), and where equations for logit( pRst ) are given in
equations 4.2a-4.2d.
The probability of response on the treatment arm over both sensitive and insensitive subjects
is then:

E (Y | T  1)  pRE  (1  pS ) pR01  pS pR11 ,
where pS is the probability that any patient is sensitive to treatment.
The expected probability of response over all subjects on the control arm is then:

E (Y | T  0)  pRC  (1  pS ) pR 00  pS ( pR 10 ).
The marginal probability of response over both treatment arms is:
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1

1

pR  E (Y )   ( pRst | S  s, T  t ) Pr( S  s) Pr(T  t )
t 0 s 0

 pR 00 (1  pS ) Pr(T  0)  pR10 pS Pr(T  0)  pR01 (1  pS ) Pr(T  1)  pR11 pS Pr(T  1).
If subjects are randomly assigned to either treatment arm with probability 0.5, then

pR  0.5 (1  pS )( pR 00  pR 01 )  pS ( pR 10  pR 11 )   ( pRE  pRC ) / 2.
5. Power for the Adaptive Signature Design
5.1 Power for the Overall Treatment Effect
For a study with n patients, the power of a two-sided  -level test to detect a difference in
response between two treatment arms with equal sample size is approximately:
1/2


4

(

)

(1

)
p
p
z
p
p



RE
RC
11 


n

Power = 1     
1/2 
  p (1  p ) 2  p (1  p ) 2  

RE
RC
RC
  R E
n
n  

(5.1)

(Freidlin & Simon, 2005 [54]) where  is the type II error, () is the cumulative
distribution function for the standard normal distribution, pRE and pRC are probability of response
in enhanced and standard treatment arms respectively, 1 is the portion of the Type 1 error
allocated to the overall test, z1 is the (1   ) percentile of the standard normal distribution, and

p

pRE  pR C
2

. For equal probability of treatment assignment 0.5 to each group, p  pR . The

formula is valid for n1 p  5. Power calculations based on the continuity corrected arcsine
transformation (Dobson & Gebski, 1986 [37]) can offer more accurate power estimations
especially for small sample sizes and for proportions close to 0.
5.2 Power for Treatment Effect in Predicted Subset of Patients
Let psens and pspec denote the sensitivity and specificity of the sensitivity status prediction
method. The purpose of ASD is to predict sensitivity status for stage 2 patients, using a model
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built on the training set (stage 1 patients), and gene expression from the stage 2 patients reserved
for prediction. The probability that a selected patient is sensitive (the positive predictive value
PPV) is

PPV 

( pS )( psens )
.
( pS )( psens )  (1  pS )(1  pspec )

(5.2)

The expected probability of response for a subject on the treatment arm in the selected subset
is pR  E  PPV ( pR11 )  (1  PPV )( pR01 ); for a subject on the control arm the expected
probability of response is pR  C  PPV ( pR10 )  (1  PPV )( pR00 ); if there is no gene main effect,
then pR10  pR00 , and p C  pC . In either case, the expected sample size of the predicted subset
of patients in stage 2 is

n2  n2  ps psens  (1  ps )(1  pspec )  ,
and the power of the subset comparison using Stage 2 patients predicted to be sensitive to
treatment is (Freidlin & Simon, 2005 [54]):
1/2



4 
 ( pR  E  pR  C )  z1 2  p (1  p )


n2 



1     
.
1/2 


2
2


  pR  E (1  pR  E ) n  pR  C (1  pR  C ) n  
2
2 



(5.3)

where  2 is the portion of the Type I error allocated to the test for the predicted subset. Note that
while equation 5.1 is for all subjects in the study, the power for subset prediction (5.3) is for the
subset of the stage 2 patients predicted to be sensitive to treatment. However it is a function of the
sample size of the training set through psens and pspec , which are used to calculate PPV, which in
turn is used to calculate pR  E and pR  C in equation 5.3. Also note that this equation does not take
into account how much the power of the subset test increases the power of the ASD method over
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the power for the overall treatment effect alone. In the ASD method, significance is declared if
there is either a significant overall effect or a significant subset effect.
5.2.1

Sensitivity and Specificity of Prediction Method

Power of the subset comparison is a function of the sensitivity psens and specificity pspec , of
the prediction method as well as pS , the probability of a patient being sensitive to treatment, and

n2 , the sample size for Stage 2. As psens and pspec increase, PPV and pR E also increase, thus
increasing effect size in the subset. Sensitivity and specificity of the ASD method are in turn a
function of the sample size for stage 1 ( n1 ), the magnitude of the difference in differential
expression between treatment arms for predictive genes (for the DR step), and the amount of
overlap in multivariate distributions of gene expression profile of selected genes between
sensitive and nonsensitive subjects. To the extent there is overlapping space between the
sensitivity-status specific multivariate distributions of the predictive genes, then no matter how
large the sample size n1 , the predictor will not be able to achieve perfect classification accuracy,
and psens and pspec will not approach 1 even as n1 becomes very large.
5.2.2

Sample Size Planning for the Simple Two-Class Problem in a High-Dimensional

Setting
For the two-class problem, Dobbin & Simon (2007 [36]) outline a method to calculate
PCC(n1) (probability of correct classification given a training set sample size of n1) in a high
dimensional setting, taking into account distribution of gene expression for the two classes. It is
assumed a small proportion of genes m/p is predictive of class status. If PCC(n1) is calculated for
each class, then this gives estimates for sensitivity and specificity for the classification method. If
a way can be found to apply or adapt this method to the ASD setting, then psens and pspec could
be calculated as a function of n1 and used to derive quantities in (5.3) to estimate power for the
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subset of patients in Stage 2 predicted to be sensitive to treatment. Their method (referred to as
D&S) takes into account variation in both the DR and the classification step.
Now the normal approximation sample size formula, applied to the training set, (and
assuming gene expression for one differentially expressed gene) is:

n1  4

2
(tn 2,1 /2  tn 2,1  )2 ,
(2 )2
1

(5.4)

1

where 2 is the difference between class means,  2 is the within-class variance, 1   is the
specificity associated with correctly identifying a gene that is not differentially expressed,

tn1 2,1 /2 is the quantile function of the central t-distribution with n1  2 degrees of freedom at
probability 1   / 2 – i.e.

tn1 2,1 /2  Tn12 (1   / 2) , where Tn12 () is the inverse cumulative

distribution function for a central t-distribution with n  2 degrees of freedom.
Dobbin & Simon (2007 [36]) derived the following approximate formula for the power for
equation (5.4):


1    Tn1 2 



n1  tn1 2,1 /2  ,


(5.5a)

where Tn 2 () is the cumulative distribution function for a central t-distribution with n  2
degrees of freedom. The formula derived by Chow, Shao, & Wang (2002 [26]) takes into account
the fact that power is under the alternative hypothesis and therefore uses the cumulative
distribution function for the noncentral t-distribution:

|



2
1    1  Tn1  2  tn01  n11  2,1 /2

1
1



n01 n11




,




(5.5b)

where tn01  n11 2,1 /2 is the quantile function for a central t-distribution with degrees of freedom

n01  n11 (where n01 and n11 are class-specific sample sizes on the training set - n01  n11  n1 ),
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and evaluated at quantile 1   / 2, and Tn2 ( |  ) is the cumulative distribution function of the
noncentral t-distribution with n1  2 degrees of freedom and noncentrality parameter  .
Now (5.5a) and (5.5b) are expressions for power to detect a difference between two groups
using one differentially expressed gene. Dobbin & Simon also derived an expression for a linear
classifier with m differentially expressed genes with equal effect sizes 2 /  and p  m
nondifferentially expressed genes (details in Appendix and in D&S). When prior class
probabilities are equal,

 
PCC (n1 )   
 
1


m(1   )
m(1   )  ( p  m)


,



(5.6a)

where 1   is sensitivity or power for correctly selecting any differentially expressed gene, 1
is the largest eigenvalue of the correlation matrix of the genes (see Schott, 2005 [146] ), and

1   is specificity for correctly identifying a non-differentially expressed gene. Each
differentially expressed gene has difference in class means 2 , and both predictive and
nonpredictive genes have within-class standard deviation  .
This lower bound for PCC (n1 ) in 5.6a takes correlation between genes into account, using
properties of extremal eigenvalues (Schott, 2005 [146] ). However in simulations and applications
involving real data sets in D&S, it was found that this approach tended to be overly conservative,
and that an equation for PCC(n1) assuming gene expression independence was either accurate
(accurately estimated the required sample size) or conservative (the sample size was higher than
required). The equation assuming gene expression independence takes advantage of the fact that
under that assumption,


PCC (n1 )   



1  1 . The equation then becomes:

m(1   )
m(1   )  ( p  m)


 ,


(5.6b)
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Now in many settings (including the ASD setting), the populations of sensitive and
nonsensitive patients are unlikely to be equal. In this case, if equation 5.6a is applied to class
prediction, the equation becomes:

 
PCC (n1 )  pS  
 
1

 
(1  pS ) 
 
1

where k 

m(1   )  k
m(1   )  ( p  m)

m(1   )  k
m(1   )  ( p  m)











1  pS
1
log
. As before, if gene independence is assumed, then
2
pS

(5.6c)

1  1 and the two

sides of the equation are approximately equal. Dobbin and Simon also showed how to modify
5.6a to control PCC in each class (particularly the smaller class, which will have a lower PCC).
This formula for a linear classifier is conservative and does not assume Bayes rule, but under
this approach, as n1 becomes large, PCC (n1 ) does approach PCC (), the probability of correct
classification assuming the Bayes rule is the normal classifier and assuming independence
between genes.
Then D&S used (5.5a) to eliminate 1   in (5.6a). The equation for the simple two-class
problem (which is not equivalent to the ASD setting), assuming equal prior class probabilities and
based on the normal approximation sample size formula and assuming gene independence is then:



m




Tn1  2 
n1  tn1  2,1 /2 





,
PCC (n1 ,  )  
1/2 

  mTn  2   n1  tn 2,1 /2    ( p  m)  

1
1



 


(5.7)

where PCC (n1 ,  ) is the probability of correct classification given sample size n1 and given  .
For unequal prior class probabilities, 5.5a could be substituted into 5.6c instead. Note that
equation 5.5b could also be substituted into equation 5.6a or 5.6c in which case the cumulative
distribution function for the noncentral t-distribution is used. For a given n1 , (5.7) can be used to
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find an optimal  for gene selection that will maximize PCC (n1 ). It can also by extension be
used to estimate PCC for different n1 .
Now the value of the quantile function for the t-distribution ( tn1 2,1 /2 ) included in (5.5a) and
(5.5b) is directly related to a DR method often used in the two-class setting. This DR method is
based on class-specific parameters only and is, for each gene k:

tDk 

( ˆ1k  ˆ 0 k )

ˆ k 2 (1/ n1  1/ n0 )

, k  1,..., p,

(5.8)

g

where ˆ k g 2 is the variance pooled over response status group for gene k on the training set, ˆ gk
are class -specific means for gene k on the training set, and ng , g {0,1}, is the sample size of
subjects specific to class g on the training set; i.e. - n0  n1  nD . In this DR method, t Dk is used to
evaluate gene k based on a t-statistic with n1  2 degrees of freedom. If the absolute value of the
t-statistics for gene k exceeds tn1 2,1 /2 , then the gene is selected. Next note that the cumulative
distribution function in (5.5), which is used to approximate sensitivity for gene selection,
decreases with increasing tn1 2,1 /2 , and increases with increasing values of


n with  held
 1

constant. In fact, if effect size and n1 are sufficiently large, so that  can be kept very small to
minimize the quantity  ( p  m) in the denominator (also assuming p-m is not too large), then

 m1/2
PCC (n1 ,  ) will approach  
 


 , which is the probability of correct classification


assuming the Bayes rule is known and that it is the normal classifier, and assuming gene
independence.
Note that (5.5a) and (5.5b) are expressions for power or sensitivity of gene selection, and
therefore the equations are a function of the DR step. From the same equation it can be seen that
the sensitivity of the DR step is a function of effect size and sample size n1. Reducing  reduces
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the sensitivity but increases specificity 1   . Note that the DR step can take advantage of
increasing values of n1 so that, with

n1 large enough, high sensitivity (and specificity) for gene

selection can be obtained even with smaller values of


. However, even if the DR step perfectly


separates out the predictive genes, the probability of correct classification will be limited by the
effect size

2



, which is independent of n1. Subjects are classified one at a time, not as a group.

No matter how large n1 , the sample size for each subject i in the validation set is still 1, and
classification decisions are based on the z i vector for the subject and the difference in
sensitivity-status specific distributions of the different z i .
5.2.3

Dimension Reduction and the Adaptive Signature Design

The two main differences between settings for ASD and D&S are related to distributions for
sensitivity status for ASD, and difference in probability of response of sensitive patients between
treatment arms. In the ASD setting, expression distribution of predictive genes depends on
sensitivity status of patient, which is unknown, but is being predicted. Sensitivity status is
measured by the extent to which probability of response for a patient is greater in the treatment
arm than in the control arm. The DR step can be motivated by the fact that, assuming there are
sensitive patients enrolled in the study, then expression for predictive genes should have a greater
difference in response status-specific distributions in the treatment arm than in the control arm,
whereas nonpredictive genes should show little or no difference. The DR method used in
simulations in Freidlin, Jiang, & Simon (2010 [36]) compares differential expression between
responders and non-responders in the treatment group to differential expression in the control
group. The equation is:

tDD k 

( ˆ11k  ˆ 01k )  ( ˆ10 k  ˆ 00 k )

ˆ k 2 (1/ n11  1/ n01  1/ n10  1/ n00 )

, k  1,..., p,

gt
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(5.9)

where ˆ kgt 2 is the variance pooled over each combination of treatment-specific and response
status-specific groups for gene k on the training set, ˆ gtk are class and treatment arm-specific
means for gene k on the training set ( g {0,1}, t {0,1}), and ngt is the sample size of subjects
specific to class g and treatment arm t on the training set; i.e. - n00  n01  n10  n11  n1. Note
that in a DR step for gene selection t DD k can be evaluated as a t-statistic with n1  4 degrees of
freedom, assuming distributions of means are approximately normally distributed. The selection
criteria could be based on the absolute value of the t-statistic: if | tDD k | tn1 4,1 */2 , then gene k is
selected.
The expression for power assuming one gene with a difference in differential expression
between the two treatment arms can be derived as follows:

( ˆ11k  ˆ 01k )  ( ˆ10 k  ˆ 00 k )

ˆ k 2 (1/ n11  1/ n01  1/ n10  1/ n00 )

 t1 /2,n11  n01  n10  n00 4

gt

Under the alternative hypothesis that   0, after ignoring a small term of value   / 2 , it
follows that:

|





*
2

,
1    1  Tn01  n11  n10  n00  4 tn01  n11  n10  n00  4,1 /2

1
1
1
1 
*





n01 n11 n10 n00 


(5.10)

*
where here 2  (11k  01k )  (10 k  00 k ) is the mean difference in differential expression

between the treatment and control arms,  *2 is the variance pooled over response status and
treatment arm, the ngt are the class and treatment arm-specific sample sizes on the training set,

tn01 n11 n10 n00 4,1 /2 is the quantile function for the central t-distribution with degrees of freedom
n01  n11  n10  n00  4 , and Tn01 n11 n10 n00 4 ( |  ) is the cumulative distribution function of the
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noncentral t-distribution with n01  n11  n10  n00  4 degrees of freedom and noncentrality
parameter  .
Now in order to calculate 2 * and  *2 we need expectation of (predictive) gene expression
given sensitivity status E (Z | S  s), the proportion of sensitive patients pS , the proportion of
sensitive patients on each treatment arm who respond pRS 1|T t and the proportion of nonsensitive
patients who respond pRS 0|T t . The equations for response status and treatment arm specific gene
expression means (  gt ) for predictive genes, are:

E ( Z | Y  1, T  1)  11 

pS pRS 1,T 1 E ( Z | S  1)
pS pRS 1,T 1  (1  pS ) pRS 0,T 1



(1  pS ) pRS 0,T 1 E ( Z | S  0)
pS pRS 1,T 1  (1  pS ) pRS 0,T 1

.

(5.11a)

E ( Z | Y  0, T  1)  01


pS (1  pRS 1,T 1 ) E ( Z | S  1)
pS (1  pRS 1,T 1 )  (1  pS )(1  pRS 0,T 1 )

E ( Z | Y  1, T  0)  10 



(1  pS )(1  pRS 0,T 1 ) E ( Z | S  0)
pS (1  pRS 1,T 1 )  (1  pS )(1  pRS 0,T 1 )

pS pRS 1,T 0 E ( Z | S  1)
pS pRS 1,T 0  (1  pS ) pRS 0,T 0



.

(5.11b)

(1  pS ) pRS 0,T 0 E ( Z | S  0)
pS pRS 1,T 0  (1  pS ) pRS 0,T 0

. (5.11.c)

E ( Z | Y  0, T  0)  00


pS (1  pRS 1,T 0 ) E ( Z | S  1)
pS (1  pRS 1,T 0 )  (1  pS )(1  pRS 0,T 0 )



(1  pS )(1  pRS 0,T 0 ) E ( Z | S  0)
pS (1  pRS 1,T 0 )  (1  pS )(1  pRS 0,T 0 )

.

(5.11d)

2
The variances for response status and treatment arm specific gene expression ( gt ) , for

predictive genes, are:
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Var( Z | Y  1, T  1)
  211 

pS pRS 1,T 1 ( S21   S21 )
pS pRS 1,T 1  (1  pS ) pRS 0,T 1



(1  pS ) pRS 0,T 1 ( S20   S20 )
pS pRS 1,T 1  (1  pS ) pRS 0,T 1

 112 .

(5.12a)

Var ( Z | Y  0, T  1)   012



pS (1  pRS 1,T 1 )( S21   S21 )
pS (1  pRS 1,T 1 )  (1  pS )(1  pRS 0,T 1 )



(1  pS )(1  pRS 0,T 1 )( S20   S20 )
pS (1  pRS 1,T 1 )  (1  pS )(1  pRS 0,T 1 )

 012 .

(5.12b)

Var( Z | Y  1, T  0)   102



pS pRS 1,T 0 ( S21   S21 )
pS pRS 1,T 0  (1  pS ) pRS 0,T 0



(1  pS ) pRS 0,T 0 ( S20   S20 )
pS pRS 1,T 0  (1  pS ) pRS 0,T 0

 102 .

(5.12c)

Var( Z | Y  0, T  0)   002



pS (1  pRS 1,T 0 )(  S21   S21 )
pS (1  pRS 1,T 0 )  (1  pS )(1  pRS 0,T 0 )



(1  pS )(1  pRS 0,T 0 )( S20   S20 )
pS (1  pRS 1,T 0 )  (1  pS )(1  pRS 0,T 0 )

 002 .

(5.12d)

Now note that a pooled standard deviation for  * assumes that variances in each of the four
groups are equal. However based on equations 5.12a through 5.12d, the variances cannot be
expected to be equal. Sample size calculations for unequal variances using the noncentral tdistribution have been presented in Harrison and Brady (2004 [72]). These use adjustments for
degrees of freedom based on Satterthwaite (1946 [142]) or Welch (1947 [172]). These methods
can also be used to modify degrees of freedom  for the t-statistic ( tn01 n11 n10 n00 4,1 /2 ) in 5.10
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to account for the unequal variances. For example based on Satterthwaite’s formula (1941 [143])
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The formula for power (or sensitivity to correctly identify any gene with a significant
difference in differential expression between the two arms) in 5.10 is then modified for unequal
variances as follows:



1    1  T  t ,1 /2
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 012  112  102
n01



n11



n10



 002
n00



.





(5.13)

Again, for each treatment group, these are calculated from the proportion of sensitive
patients, the proportion of sensitive subjects expected to respond and the proportion of
nonsensitive subjects expected to respond. The expected sample sizes ngt given a training set of
size n1 and equal allocation of subjects to the two treatment arms are:

n11  0.5n1{ pS pRS 1,T 1  (1  pS ) pRS 0,T 1 }

n01  0.5n1{ pS (1  pRS 1,T 1 )  (1  pS )(1  pRS 0,T 1 )}
n10  0.5n1{ pS pRS 1,T 0  (1  pS ) pRS 0,T 0 }
n00  0.5n1{ pS (1  pR01,T 0 )  (1  pS )(1  pRS 0,T 0 )}
Note that, on the control arm, if there is no difference in probability of response between
sensitive and nonsensitive patients, then pRT 0  pRS 1,T 0  pRS 0,T 0 , and

n10  0.5 pRT 0 n1 and n00  0.5(1  pRT 0 )n1. There will also be simplifications for equations for

 gt2 and  gt .
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5.2.4

Probability of Correct Classification and the Adaptive Signature Design

The previous section has shown how to modify PCC (n1 ) to take into account the DR step in
the ASD setting (equation 5.13) as opposed to the simple two-class problem. Now, the extent that
the DR step correctly selects genes with a difference in differential expression between the two
arms, the simple linear classifier proposed by D&S and applied to the ASD setting is left with the
selected genes from the vector z i to make a classification decision for sensitivity status for each
subject. Remember that 2 /  has been previously defined as the effect size for predictive
genes, between sensitive and nonsensitive subjects.
Using this approach, assuming equal class sizes and gene independence, equation 5.6b can be
modified as follows:
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(5.14)

If class sizes are not equal, as is likely for sensitivity status in the ASD setting, the method by
D&S to adapt this equation to control PCC in the rarer class can be used. Alternatively we can
modify equation 5.6c as follows (again setting

  1 for gene independence):
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6. Limitations and Future Work
There are some differences between the classification of sensitivity status in an ASD setting
and classification in the simple two-class problem outlined in D&S. For example, sensitivity
status does not become known on the training set. Instead a CV method is used which chooses a
set of tuning parameters which optimize sensitivity status prediction. Simulations need to be
performed to evaluate what effect this has on sample size and power estimation. Also the use of
the Student’s t-distribution assumes that the sample means ˆ gt are at least approximately
normally distributed. This assumption is likely to break down with small sample sizes ngt ,
because of the mixture of normal distributions. A nonparametric approach based on ranks along
the lines of those described in Conover and Iman (1981 [29]) or power and sample size methods
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for logistic regression methods on Shieh (2000 [149]) and Self, Mauritsen, & Ohara (1992 [148])
may be avenues for exploration.
Still another approach may be to use an Expectation Maximization (EM) algorithm
(Dempster, Laird, & Rubin, 1977 [34]) to attempt to retrieve the distributions based on sensitivity
status, which is a latent variable. An EM approach for Gaussian mixtures involving latent
variables is outlined in Bishop (2006 [10]). A Bayesian method is also outlined which addresses
“significant limitations in the maximum likelihood approach”. If an EM or Bayesian method were
to be adopted, the challenge would still remain of incorporating a power and sample size method
for the approach.
Finally, another limitation is that the method described in this work assumes equal withinclass covariance matrices for each class. The works of Freidlin & Simon assume unequal
covariance matrices for each sensitivity status class.
Appendix
Linear Classifier for PCC(n)
Linear classifier with weights 1 for genes that are selected and 0 for those that are not,
assuming centering of gene expression class means around 0, and assuming equal prior
probabilities: i.e. the linear classifier makes the following classification decision:

gˆ i  I  w'zi  0  . Here w is a vector of weights of 0’s and 1’s. This is consistent with a DR step
for gene selection. In the case of unequal prior probabilities, the equation is


1  1 
1
gˆ i  I  w'z i  log
.
2
1 

The equation for probability of correct classification for this linear classifier assumes m
differentially expressed genes, all with same effect size 2 /  , as well as p  m
nondifferentially expressed genes. More details can be found in Dobbin & Simon (2007)
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Note on Equation for Probability of Correct Classification
A method is outlined in D&S for deriving PCC () , which is the probability of correct
classification given that the Bayes rule is known and that it is the normal classifier (Linear
Discriminant Analysis or LDA). The equation for PCC () can be derived from LDA by setting
elements of the μ1 and μ 0 vectors of expected gene expression means to 1 and -1 respectively for
predictive genes and sensitive , and both to 0 for nonpredictive genes. The pooled correlation
matrix Σ1  Σ0 can be diagonal for both predictive and nonpredictive genes. Correlation between
genes can also be taken into account. In this setting, it can be shown that the normal classifier is
itself normally distributed since it is a linear combination of the elements of the multivariate
normally distributed vector z i vector times a constant. This is important because the classifier is
essentially a test statistic that makes classification decisions at the unit level - for each subject i.
Therefore asymptotic normality cannot be invoked, as is often done for test statistics when testing
for difference between two groups. However one limitation of using this method in the ASD
context is that although gene expression is assumed to be multivariate normally distributed, the
relationship with expected value of gene expressions and response is assumed to follow a logistic
model. So we can expect PCC () assuming LDA is the Bayes rule to be optimistic if the logistic
model is the true model, since LDA has superior performance to logistic regression when
assumptions for LDA are true. However what we are really after is PCC (n1 ) , which is the
probability of correct classification given the sample size on the training set. The expression for

PCC (n1 ) derived in Dobbin & Simon (2007 [36]) does not assume LDA, and the sample sizes
given are shown to be conservative in many cases.
Bayes rule assuming the normal classifier
It is assumed that, at least after log normalization, gene expression between classes is
multivariate normally distributed, and that variance (or covariance matrix) for the classes are the
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same. In addition it is assumed that gene expression is log normalized and standardized in such a
way that the mean vector for the two difference classes is centered around 0. The reason for this
is that, for linear discriminant analysis, quadratic terms drop out and, if gene expression vector zi
is multivariate normally distributed, then the classifier itself is normally distributed since it is a
linear combination of the multivariate normally distributed variable zi . Specifically

   1
1

LLRi  log  1     zi  μ1  ' Σ 1  zi  μ1    zi  μ0  ' Σ 1  zi  μ0  
2

 0   2
  
1

 log  1    μ1  μ0  ' Σ 1zi   μ1  μ0  ' Σ 1  μ1 + μ0   .
2

 0  
And if the class mean vectors are centered around 0, this becomes

 
 
LLRi  log  1    μ1  μ0  ' Σ 1zi   log  1   a' zi  . The classifier itself is then
 0 
 0 
normally distributed: if μ1  1 and μ0  1 then

 
 1  1 
1
LLRi  log  1    2μ1 ' Σ 1zi  , or log 
   2μ1 ' Σ zi  .


 1 
 0
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PROPERTIES OF ADAPTIVE CLINICAL TRIAL SIGNATURE DESIGN IN
THE PRESENCE OF GENE AND GENE –TREATMENT INTERACTION
Abstract
In this work properties of the adaptive signature design are investigated through simulation.
The scenarios include presence of gene expression-treatment interaction effect only, presence of
both gene expression main effect and expression-treatment interaction, and presence of
expression, treatment, and expression-treatment interaction. Classification methods are examined
which both include and exclude gene expression main effect. It was found that, under the
scenarios considered, the models which exclude expression main effect while including treatment
main effect and expression-treatment interaction often had superior performance to models which
included expression main effect.
Key Words: classification; machine learning; dimension reduction; interaction; melanoma;
clinical study.
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1. Introduction
Freidlin & Simon (2005 [54]) introduced the adaptive signature design (ASD) to predict a
subset of patients more sensitive to treatment. A flowchart of this method is shown in Figure 1.
The first stage of the two-stage design is used to develop a predictive model prospectively. When
the predictive model is built, response and gene expression data is available for Stage 1 patients.
Response information becomes available after predictions are made. The classification rule is
then applied to the Stage 2 patients to predictive a subset of patients more sensitive to treatment.
Gene expression for Stage 2 patients is available for prediction purposes, but outcome results are
not yet available (or if they are they are not used).
When results for both Stage 1 and Stage 2 are available, an overall treatment-control
comparison test is conducted over all the patients. In addition a treatment-control comparison is
conducted on Stage 2 only. The treatment is considered significant if either test is significant.
Type 1 error is controlled by constraining the sum of the two alpha levels for these two tests.
Freidlin, Jiang, & Simon (2010 [55]) extend this approach using cross validation to apply the
prediction model over all the patients (both Stage 1 and Stage 2). Many classification methods
can be employed in this approach. The specific example used in the Freidlin & Simon work was a
weighted voting single-gene logistic regression model with treatment main effect and gene
expression-treatment interaction. The simulations included scenarios in which the probability of
response for sensitive subjects was the same as that for nonsensitive subjects except in the
treatment arm. This equates to scenarios involving only treatment- expression interaction, but no
main effects for expression or treatment.
Purpose of Study
In Cambon, Baumgartner, Brock, Cooper, & Rai (2015a [19]) and Cambon, Baumgartner,
Brock, Cooper, & Rai (2015b, [20]) methods were proposed for modifying or extending
nonparametric and parametric classifiers for use in an ASD setting. In this work empirical power
of these methods is evaluated under scenarios which include treatment expression interaction
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only, expression main effect and treatment interaction, and both treatment and expression main
effects together with interaction.
Organization of Study
Section 2 covers the background for the ASD model. Section 3 outlines extensions and
modifications of ASD method, and Section 4 describes the simulation study. Results are in
Section 5, and discussion is found in Section 6.
2. Background of ASD Model
The sample sizes of subjects for Stage 1 and Stage 2 are n1 and n2 respectively, and the total
sample size is n  n1  n2 . Stage 1 serves as the training set where the prediction models is built
(using nested cross validation), and Stage 2 patients serve as the final validation set where patient
sensitivity is predicted.
A subject that is sensitive to treatment has a greater probability of response on the treatment
arm than on the control arm. The probability that any new subject accrued into the study is
sensitive is pS , and is the probability of response given Si  s and Ti  t , where Si {0,1} and

Ti {0,1} are random variables for patient sensitivity status and patient treatment arm status
respectively, and can take on values of 0 and 1. The number of evaluated genes is p. Within these
p genes it is assumed that there is a set of predictive genes which can be used to predict
sensitivity status of subjects. Without loss of generality, it is assumed that the first m genes,

k  1,..., m, are the predictive genes. The p-length vector of gene expression for subject i is
denoted by random variable Z i , and the kth element of that vector (gene expression for the kth
gene for subject i) is Z ik . Fixed realization of these quantities are denoted by lower case letters.
The model relating expected value of gene expression for predictive genes

E (Zik ), k  1,..., m , patient sensitivity and treatment arm status to response probability pRi can
be written:
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 pRi | Si , Ti
logit( pRSTi )  logit pR i | Si , Ti , E ( Zi )  log 
 1  pR | Si , Ti
i

m
(1  Si ){ 2 k E ( Zik | Si  0)  12 k Ti E ( Zik | Si  0)}
 
.
k 1   Si { 2 k E ( Z ik | Si  1)  12 k Ti E ( Z ik | Si  1)}







   0  1Ti



(4.1)

Now, if expected value of expression for predictive gene depends only on sensitivity status of
subject, (i.e.- E (Zik | Si  s)  sk ) then subscript i can be dropped since probability of response
no longer depends on i, and for a sensitive subject on the treatment arm:

logit( pR11 )  logit( pR | S  1, T  1)  0  1     2 j 1k  12 k 1k ,
m

k 1

and similarly for pR10 , pR 01 , and pR00 .
A multi-gene logistic regression model can be used in an ASD setting. For example using
maximum likelihood estimates from the training set substituted for true unknown parameter
values, and using genes selected based on their estimated predictive strength in place of the true
unknown predictive genes, and zik the expression value for subject i and selected gene k in the
validation set in place of  sk is:
m*





logit( pˆ Rti )  logit( pˆ R | ti , zik * )  ˆ0  ˆ1ti   ˆ2 k* zik*  ti ˆ12 k* zik* ,
k *1

where k*  1,..., m * are the m* genes predicted to be sensitive (using the DR step), and where
information to predict si must be derived from the zik * in place of the  sk , as well as the
estimated model coefficients, and their relationship with ti. The treatment arm odds ratio for
subject i is then
m*


ORi  exp logit(pˆ R1i )  logit(pˆ R0 i )   exp  ˆ1   ˆ12 k * zik*  .
k * 1
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As in the Freidlin & Simon, prediction of sensitive patients can also be done using weighted
voting on the odds ratios for each of the single gene models for the selected genes. The odds
ratios for each of selected gene k* is then





ORik*  exp logit(pˆ R1ik* )  logit(pˆ R0ik* )   exp ˆ1k*  ˆ12k* zik* .
Figure 5 gives more details. Nested validation sets are used for selection of the final tuning
parameter set, and the final validation set is used for final prediction of sensitive patients. Note
that in the Freidlin & Simon’s ASD single gene model, parameter

 2 for gene expression main

effect is not included. This is equivalent to modeling no gene expression main effect.
3. Extensions and Modifications of ASD Method
The following classification methods were used in the simulation scenarios. They were
outlined in detail in Cambon, Baumgartner, Brock, Cooper, Wu, & Rai (2014a [19]) and in
Cambon, Baumgartner, Brock, Cooper, Wu, & Rai (2014b [20]).
1. Same weighted voting logistic regression single gene model as in Freidlin & Simon: no
parameter for gene main effect (  2 constrained to be 0). This is called the LRTWV model.
2. Same model as #1 above, but including both main effects and interaction; i.e. - 1 ,

 2 and

12 . This is called the LRTGWV model.
3. From Cambon et al. (2014a [19]):
a. Weighted voting kernel density analysis using posterior odds ratio- which is the
odds ratio based on treatment arm and class-specific posterior probabilities. In
terms of effects included in model, KDATWV corresponds to LRTWV, and
KDATGWV corresponds to LRTGWV. Note this since these are single gene weighted
voting models, independence is assumed between genes. This is also the case for
#4 and #5 below.
4. From Cambon et al. (2014b [20]):
103

a. Weighted voting quadratic discriminant analysis (QDATWV and QDATGWV) using
posterior treatment odds ratio.
b. Linear discriminant analysis weighted voting (LDATWV and LDATGWV) posterior
treatment odds ratio.
The LRTWV weighted voting model described in Freidlin & Simon excludes the term for gene
expression main effect. In order to have comparable models for KDATWV, QDATWV, and
LDATWV, the class-specific densities for expression on the control arm were constrained to be
equal in the TWV models.
4. Simulation Study
The distribution of expression of predictive genes depends on sensitivity status; i.e.-

Z | S  s ~ MVN(μs , ΣS ); i  (1,...,n1,...,n), k  (1,..., m), where Z is the n by p matrix of
gene expression, but it is independent of treatment assignment; the results of the assay are not
used to assign subjects to a specific treatment arm.

Pr(Zik , Ti )  Pr(Zik ) Pr(Ti ), i  1,..., n; k  1,..., p. The distribution of expression of predictive
genes for sensitive patients is not independent of response:

Pr(Zik , Yi )  Pr(Zik ) Pr(Yi ); i s.t. Si  1, k  1,..., m but it is independent of response for
nonsensitive patients: Pr(Zik , Yi )  Pr( Zik ) Pr(Yi ); i s.t. Si  0, k  1,..., m. For the nonpredictive genes, expression is independent of response for all patients; i.e.:

Pr(Zik , Yi )  Pr(Zik ) Pr(Yi ); i  1,..., n; k  m  1,..., p. The nonpredictive genes are constrained
to have the same mean as the predictive genes for non-sensitive subjects, but they are allowed to
2
have different variance: i.e.: Zik ~ N ( 0 ,  ns ), i  1,..., n, k  m  1,..., p.

Simulation Steps
1. Fix parameters n1 and n2.
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a. In practice, methods such as those proposed by Dobbins and Simon (2011 [35])
can be used to apportion n to n1 and n2.
2. Allocate Type I error to
a.

1 and  2 .

1  0.04 and  2  0.01 were used exclusively in this work.

3. Select list of tuning parameter sets for ASD design.
a. Since all methods in this simulation were based on odds ratios similar to those
used in Freidlin & Simon, the list of tuning parameter sets are similar to those
outlined in that work, however a wider range was included. For example the list
consisted of 9 sets of tuning parameters (vs. 3 in Freidlin & Simon) with p-values
of 0.01 as well as 0.02 included for the dimension reduction step.
4. Simulate subject sensitivity status over all n subjects using Bernoulli distribution with
parameter pS .
5. Conditional on Si, i, i  1,..., n1 ,..., n, and k  1,..., m, simulate gene expression Z ik for
predictive genes.
6. Simulate gene expression for non-predictive genes, k=m+1,…,p.
7. Divide training set i  1,..., n1 into nested train and validation sets.
a.

In this work, 10-Fold cross validation (CV) was used; approaches such as nested
bootstrap could also be used.

8. Use each set of tuning parameters to predict patient sensitivity on the nested validation sets in
the training set i  1,..., n1;
a. If CV is used, this results in exactly 1 prediction for each subject in the training
set for each of the tuning parameter sets.
b. It was found that use of low p values (such as 0.01) to select a small number of
genes may cause the simulation to fail, since at times no genes will be selected.
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To prevent this, code was added to select a minimum of 3 genes. This option
permitted a wider choice of tuning parameter p-values to select genes.
9. Select the set of tuning parameters that results in the lowest p-value of treatment-control
comparison of predicted sensitive patients, and this set for prediction of sensitive patients in
the validation set.
10. Repeat these steps B times for each value of pS used in the simulation.
In this work there were B= 100 simulations for each scenario in Tables 9 through 13.
Tables 14 and 15 used 1000 simulations for each scenario in order to elucidate differences
between methods.
11. Conserve Type 1 error  as described in Figure 5 using 1 for the overall test and  2 for
the subset test.
Simulation Scenarios
The following parameters were common to all simulations:
1) The number of predictive genes p*=10; total number of genes p=1000.
2) Type 1 error for either the overall test or the subset test was controlled at level 0.05 by setting

1  0.04 and  2  0.01.
3) The distribution of genes used was the same as in Freidlin, Jiang, & Simon (2010 [55]):
a. For sensitive patients, expression of predictive genes is normally distributed with
mean of 1 and variance of 0.25;
b. For nonsensitive patients, expression of predictive genes is normally distributed
with mean of 0 and variance 0.01;
c. The expression of non-predictive genes is normally distributed with mean of 0
and variance of 0.25.
The following simulation scenarios were used:
1. Values for pS of 0.05, 0.07, 0.10, 0.15, 0.20, and 0.25.
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2. The combination of values for pRST used in simulation scenarios are shown for each table of
results. These include scenarios involving:
a. Only gene-treatment interaction (from the Freidlin & Simon 2005 work).
b. Gene main effect together with gene-treatment interaction.
c. Both main effects and interaction.
3. The different classification methods described in Section 3 were applied over these different
scenarios. Note that the simulation scenarios are distinct from model parameters used in the
classification methods to predict patient sensitivity.
5. Results
Tables 9, 10, and 11 include results for gene expression treatment interaction only, with Table
9 showing results with no correlation between genes, Table 10 showing results with correlation of
0.6 between predictive gene and 0.6 between nonpredictive genes, and Table 11 including smaller
sample sizes for Stage 1 and Stage 2 (100 patients for each stage instead of 200). Table 12
includes a scenario for gene expression main effect as well as expression-treatment interaction.
Table 13 includes a scenario for gene expression main effect, treatment main effect, and gene
expression-treatment interaction. Under most scenarios considered, the predictive models which
included coefficients main effect terms for treatment only (together with treatment-gene
expression interaction – the TWV models) had higher empirical power compared to models
which included both expression and treatment main effects together with interaction(all models
included treatment interaction term).
In order to compare the methods under different scenarios, additional simulations were
conducted. Since empirical power of the different methods was similar, 1000 simulation runs per
scenario were used to differentiate between the methods. Table 14 compares empirical power of
LRTWV, KDATWV, LDATWV, and QDATWV methods under scenarios similar to those used in the
Freidlin and Simon work. That is, the ratio of the variances of gene expression for predictive
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genes for sensitive subjects vs. nonsensitive subject was kept at 25 to 1. Under this scenario,
empirical power of LRTWV was slightly higher than LDATWV, which in turn was slightly higher
than QDATWV , which was slightly higher than KDATWV. Table 15 then shows empirical power of
LRTWV and LDATWV when variances of gene expression for predictive genes for sensitive subjects
vs. nonsensitive subject is kept equal (ratio of 1 to 1). Under these scenarios, the empirical power
of LDATWV is slightly higher than that of LRTWV.
6. Discussion
Relationship between Probability of Sensitivity and Power of Adaptive Signature Design
As pointed out in Freidlin & Simon (2005 [54]), when pS is small, the probability that there
is a significant overall treatment effect is small, because the sample size of sensitive subjects is
small. In this situation, there still may be a significant treatment effect in the predicted set of
sensitive patients if the treatment effect in the subset is large. As pS increases, the subset of
sensitive patients also increases, and if the treatment effect in this subset remains constant, the
probability of detecting a significant treatment effect in the subset increases. However at the same
time the probability that the overall test detects a significant treatment effect also increases. At
some point, the added value of the test of treatment effect in the predicted subset decreases,
because it is less likely that both the test over all the patients is insignificant while the subset test
is significant. This relationship is reflected in Tables 9 through 11. The “Subset only 0.01”
column, which is proportion of times that the subset test was significant when the overall test was
not, usually increases as pS increase from 0.05 to 0.15 (results for pS  0.05 not shown), and
then decreases thereafter. However the overall power of the ASD test, which is significant if
either the overall test or the predicted subset test is significant, continues to increase as pS
increases.

108

Main Effects and Interaction Terms in the ASD Model
In clinical applications, models which include interaction terms usually also include
corresponding main effect terms. For example, in a treatment subset prediction context, see
Scher, Nasso, & Simon (2011 [144]). Therefore it is interesting that the TWV models had
superior performance to TGWV models under the scenarios considered. Also KDATWV and
QDATWV models had power close to performance of LRTWV and KDATGWV and QDATGWV similar
to LRTGWV. The performance of the corresponding LDA models were slightly lower, as would be
expected since variances of predictive genes for sensitive patients were 25 times the variances of
predictive genes for nonsensitive patients.
Limitations
1. In this work the response was assumed to be categorical. However in many clinical trials,
response to treatment may be continuous. For example progression free response may be
determined from a measurement of tumor size or change in size.
2. In some works clinical covariates or gene expression results may be used to assign patients to
a specific treatment regimen; for example see Lu, Zhang, & Zeng (2013 [107]). However in
this work we limit ourselves to the situation in which the distributions of expression of
predictive genes and non-predictive genes are independent of treatment; i.e. patients are
randomized independently of results of assay.
3. Real data sets were not used to simulate gene expression. Further work needs to be done
examining the performance of the various methods with real data sets.
4. The type 1 error can be split up between the overall test and the subset test in different ways.
For example, if it is hypothesized that is only a very small (or even no) overall treatment
effect, but a large treatment effect for a subset of patients, most of the Type 1 error can go to
the predicted subset. This was the approach used in Scher et al., (2011 [144]).
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Future Work
The KNN (K Nearest Neighbors) using in Dudoit et al. (2002 [39]) uses 1 – correlation as a
distance measure to determine the nearest neighbors. The decision rule to determine class is

gˆ i  I ( pi , NN  0.5) where gˆ i is the 0-1 classification decision for subject i, and pi,NN is the
proportion of training set nearest neighbors for patient i belonging to class g=1. This approach
performed well in the Dudoit et al. work (2002 [39]). One approach to apply KNN to treatment
subset prediction would be to compare this difference in proportion across the two treatment
groups. Subjects which have a large difference in proportions would be predicted to be sensitive
(Cambon et al., 2014a [19]). However this difference in proportions does not make direct use of
the underlying distance measure (which in the Dudoit et al. work is 1 – correlation) for treatment
subset prediction. Work is underway in developing this method for treatment subset prediction.
Work is also underway to develop code for multi-gene penalized versions of LDA such as
Modified Linear Discriminant Analysis or MLDA (Xu, Brock, & Parrish, 2009 [177]). Use of
multi-gene penalized logistic regression models is another appealing avenue for exploration.
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Table 9: PR11=0.98, PR10=PR01=PR00=0.25. (Expression-Treatment Interaction Effect Only);

  0.

pS

Method

Subset .01

Subset Only
.01

ASD.overall

0.10

LRTWV

0.68

0.46

0.82

KDATWV

0.62

0.39

0.75

QDATWV

0.61

0.40

0.76

LDATWV

0.67

0.44

0.80

LRTGWV

0.57

0.38

0.74

KDATGWV

0.59

0.40

0.76

QDATGWV

0.56

0.38

0.74

LDATGWV

0.52

0.35

0.71

LRTWV

0.89

0.35

0.93

KDATWV

0.84

0.32

0.90

QDATWV

0.84

0.34

0.92

LDATWV

0.85

0.33

0.91

LRTGWV

0.79

0.31

0.89

KDATGWV

0.81

0.33

0.91

QDATGWV

0.81

0.32

0.90

LDATGWV

0.77

0.32

0.90

LRTWV

0.99

0.24

1.00

KDATWV

0.95

0.22

0.98

QDATWV

0.97

0.24

1.00

LDATWV

0.99

0.24

1.00

LRTGWV

0.92

0.23

0.99

KDATGWV

0.96

0.24

1.00

QDATGWV

0.94

0.23

0.99

LDATGWV

0.91

0.21

0.97

0.15

0.20

pS - probability any patient is sensitive; PRST-Probability of response given S=s and T=t, where S and T are
Sensitivity and Treatment indicators; Subset.01-subset test at level .01; Subset Only .01- Only subset test significant
(Overall.04 test not significant); ASD overall - overall empirical power of ASD- either Overall .04 test significant or
Subset .01 test significant; Overall .04 test empirical power at Type 1 error 0.04: 0.22, 0.36, 0.58, 0.76 – for pS =0.07,
0.10,0.15, and 0.20;LR-Logistic Regression; TWV-weighted voting model with only treatment main effect and
expression-treatment interaction; TGWV-weighted voting model with expression and treatment main effects and
interaction. Mean and variance of expression for predictive genes for sensitive patients =1 and 0.25 respectively; mean
and variance for predictive genes for nonsensitive patients =0 and 0.01 respectively. Mean and variance for
nonpredictive genes= 0 and 0.25.  - correlation within block of predictive genes and within block of nonpredicitve
genes. Correlation between the two blocks =0 for all simulations.
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Table 10: PR11=0.98, PR10=PR01=PR00=0.25. (Expression-Treatment Interaction Only);

  0.6.

pS

Method

Subset .01

Subset Only
.01

ASD.overall

0.10

LRTWV

0.59

0.38

0.74

KDATWV

0.59

0.41

0.77

QDATWV

0.62

0.43

0.79

LDATWV

0.53

0.33

0.69

LRTGWV

0.49

0.31

0.67

KDATGWV

0.52

0.36

0.72

QDATGWV

0.48

0.31

0.67

LDATGWV

0.47

0.30

0.66

LRTWV

0.85

0.33

0.91

KDATWV

0.84

0.34

0.92

QDATWV

0.81

0.32

0.90

LDATWV

0.80

0.29

0.87

LRTGWV

0.75

0.26

0.84

KDATGWV

0.68

0.26

0.84

QDATGWV

0.73

0.27

0.85

LDATGWV

0.64

0.20

0.78

LRTWV

0.95

0.21

0.97

KDATWV

0.91

0.21

0.97

QDATWV

0.92

0.22

0.98

LDATWV

0.95

0.21

0.97

LRTGWV

0.90

0.21

0.97

KDATGWV

0.87

0.20

0.96

QDATGWV

0.88

0.21

0.97

LDATGWV

0.86

0.20

0.96

0.15

0.20

See Table 9 for notation/abbreviations. Overall empirical power at Type 1 error 0.04: 0.22, 0.36, 0.58, 0.76 – for pS
=0.07, 0.10, 0.15, and 0.20.
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Table 11: Small Sample Size Simulation Scenario PR11=0.98, PR10=0.25, PR01=PR00=0.25; n1=n2=100,

pS

Method

Subset .01

0.10

LRTWV

0.08

Subset Only
.01
0.08

KDATWV

0.05

0.05

0.21

LDATWV

0.08

0.07

0.23

QDATWV

0.08

0.07

0.23

LRTWV

0.22

0.12

0.43

KDATWV

0.18

0.09

0.40

LDATWV

0.19

0.12

0.43

QDATWV

0.19

0.13

0.44

LRTWV

0.50

0.14

0.76

KDATWV

0.45

0.09

0.71

LDATWV

0.44

0.09

0.71

QDATWV

0.50

0.11

0.73

LRTWV

0.72

0.13

0.91

KDATWV

0.65

0.11

0.89

LDATWV

0.71

0.13

0.91

QDATWV

0.67

0.13

0.91

0.15

0.20

0.25

  0.

ASD.overall
0.24

See Table 9 for notation/abbreviations. Overall power at 0.04: 0.16,0.31,0.62, and 0.78 for pS=0.10,0.15, 0.20,.25.
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Table 12: Gene Main Effect, and Gene-Treatment Interaction:PR11=0.98, PR10=0.35, PR01=PR00=0.25,

pS
0.07

0.10

0.15

0.20

Method

Subset .01

Subset Only
.01

ASD.overall

LRTWV

0.10

0.07

0.26

KDATWV

0.12

0.07

0.26

QDATWV

0.11

0.08

0.27

LDATWV

0.08

0.05

0.24

LRTGWV

0.07

0.06

0.25

KDATGWV

0.09

0.07

0.26

QDATGWV

0.08

0.05

0.24

LDATGWV

0.07

0.06

0.25

LRTWV

0.43

0.35

0.57

KDATWV

0.38

0.32

0.54

QDATWV

0.44

0.36

0.58

LDATWV

0.41

0.34

0.56

LRTGWV

0.36

0.30

0.52

KDATGWV

0.33

0.27

0.49

QDATGWV

0.40

0.32

0.54

LDATGWV

0.29

0.25

0.47

LRTWV

0.77

0.39

0.85

KDATWV

0.68

0.34

0.80

QDATWV

0.72

0.38

0.84

LDATWV

0.76

0.39

0.85

LRTGWV

0.66

0.36

0.82

KDATGWV

0.65

0.36

0.82

QDATGWV

0.61

0.30

0.76

LDATGWV

0.62

0.30

0.76

LRTWV

0.90

0.33

0.94

KDATWV

0.86

0.28

0.89

QDATWV

0.89

0.32

0.93

LDATWV

0.85

0.29

0.90

LRTGWV

0.79

0.26

0.87

KDATGWV

0.79

0.27

0.88

QDATGWV

0.81

0.29

0.90

  0.

LDATGWV
0.76
0.26
0.87
See Table 9 for notation/abbreviations. Overall power at 0.04: 00.22,0.36,0.58, and 0.76 for pS =0.07, 0.10,0.15, and
0.20.
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Table 13: Sensitivity Main Effect, and Treatment Main Effect, and Sensitivity-Treatment Interaction: PR11=0.98,
PR10=0.35, PR01=0.35, PR00=0.25,   0.

pS

Method

Subset .01

Subset Only
.01

ASD.overall

0.07

LRTWV

0.07

0.00

0.78

KDATWV

0.10

0.01

0.79

QDATWV

0.06

0.01

0.79

LDATWV

0.05

0.00

0.78

LRTGWV

0.10

0.00

0.78

KDATGWV

0.11

0.00

0.78

LRTWV

0.35

0.03

0.94

KDATWV

0.30

0.02

0.93

QDATWV

0.33

0.01

0.92

LDATWV

0.26

0.03

0.94

LRTGWV

0.27

0.01

0.92

KDATGWV

0.27

0.02

0.93

LRTWV

0.67

0.01

1.00

KDATWV

0.55

0.01

1.00

QDATWV

0.58

0.01

1.00

LDATWV

0.60

0.01

1.00

LRTGWV

0.46

0.01

1.00

KDATGWV

0.51

0.01

1.00

LRTWV

0.76

0.02

0.99

KDATWV

0.76

0.02

0.99

QDATWV

0.76

0.03

1.00

LDATWV

0.73

0.01

0.98

LRTGWV

0.68

0.02

0.99

KDATGWV

0.72

0.02

0.99

0.10

0.15

0.20

See Table 9 for notation/abbreviations. Overall power at 0.04: 0.78,0.91,0.99, and 0.97 for pS =0.07, 0.10,0.15, and
0.20.
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Table 14: Comparison of TWV Methods under simulation scenarios similar to Freidlin and Simon work (unequal
variances for gene expression for predictive genes between sensitivity classes). PR11=0.98, PR10=0.25, PR01=0.25,
PR00=0.25,   0.

Method

Ps

Overall.04 Subset.01 Subset Only .01

ASD Overall

LRTWV

0.10

0.35

0.63

0.41

0.75

KDATWV

0.10

0.35

0.57

0.36

0.70

LDATWV

0.10

0.35

0.61

0.40

0.74

QDATWV

0.10

0.35

0.59

0.38

0.72

LRTWV

0.15

0.50

0.78

0.36

0.86

KDATWV

0.15

0.50

0.73

0.32

0.83

LDATWV

0.15

0.50

0.76

0.35

0.86

QDATWV

0.15

0.50

0.74

0.34

0.84

LRTWV

0.20

0.64

0.85

0.28

0.91

KDATWV

0.20

0.64

0.82

0.25

0.89

LDATWV

0.20

0.64

0.84

0.27

0.91

QDATWV

0.20

0.64

0.83

0.26

0.90

See Table 9 for notation/abbreviations.
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Table 15: Comparison of LRTWV and LDATWV methods when variances of gene expression for predictive genes are
constrained to be equal PR10=0.25, PR01=0.25, PR00=0.25,   0.

Method

Stdev

PR11

Overall
0.04

Subset
ASD
Subset.01 .01 Only Overall

LDATWV

0.40

0.90

0.53

0.24

0.08

0.61

LDATWV

0.35

0.90

0.53

0.28

0.10

0.63

LDATWV

0.30

0.90

0.54

0.34

0.12

0.66

LRTTWV

0.40

0.90

0.53

0.21

0.06

0.59

LRTTWV

0.35

0.90

0.53

0.26

0.08

0.61

LRTTWV

0.30

0.90

0.54

0.31

0.10

0.63

LDATWV

0.40

0.98

0.62

0.48

0.16

0.77

LDATWV

0.35

0.98

0.63

0.56

0.17

0.80

LDATWV

0.30

0.98

0.63

0.64

0.20

0.83

LRTTWV

0.40

0.98

0.62

0.45

0.14

0.76

LRTTWV

0.35

0.98

0.63

0.54

0.16

0.79

LRTTWV

0.30

0.98

0.63

0.62

0.18

0.82

LDATWV

0.40

0.98

0.49

0.27

0.11

0.597

LDATWV

0.35

0.98

0.50

0.35

0.14

0.633

LDATWV

0.30

0.98

0.50

0.43

0.18

0.677

LRTTWV

0.40

0.98

0.49

0.28

0.10

0.595

LRTTWV

0.35

0.98

0.50

0.33

0.13

0.626

LRTTWV

0.30

0.98

0.50

0.41

0.16

0.664

Stdev- standard deviation for gene expression for predictive genes and nonpredictive genes; difference
between means of gene expression for nonsensitive vs sensitive subjects = 1. See Table 9 for other
notation/abbreviations.
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likelihood, and calculation and application of confidence intervals.
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Designed and tested smoothing algorithm for new GE dryer. Received $1000 GE patent
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2014.
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Cambon AC, Baumgartner KB, Brock GN, Cooper NGF, Wu D, and Rai SN. Classification of
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Reviews. Model Assisted Statistics and Applications, In Press, 2014.
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Steiner RWP, Brock GN, Cambon AC, Anderson SA, Lewis JN, and Morse JH. Evaluating the
Impact of a Work Site Tobacco Smoking Ban on Healthcare Utilization among Active
Employees. Nicotine and Tobacco Research, April 2014.
Amraotkar AR, Cambon AC, Rai SN, Keith MCL, Ghafghazi S, Bolli R, and DeFilippis AP. Risk
of E. coli Contamination in Non-Municipal Waters Consumed by Mennonites versus
Other Rural Populations. The American Journal of Public Health, June 2014.
In Preparation
Amraotkar AR, Boman M, Nair R, Cambon AC, Rai SN, Bolli R, and DeFilippis AP. Sensory
Integration in Individuals with Autism Spectrum Disorders Entering White versus Black
Sensory Room.
Cambon AC, Baumgartner KB, Brock GN, Cooper NGF, Wu D, and Rai SN.
Properties of Adaptive Clinical Trial Signature Design in the Presence of Gene and Gene
–Treatment Interaction.
Cambon AC, Baumgartner KB, Brock GN, Cooper NGF, Wu D, and Rai SN.
Estimating Design Parameters in the Presence of Gene and Gene -Treatment Interaction
Using High-Throughput Informatics in Clinical Trials.
5.

VOLUNTEER SERVICE

Water and Health Development Engineer, Mennonite Central Committee, 1982-1985 – see #3
above for more detail.
GE Elfun Society – 1997-2003 – participated in numerous projects including Kentucky School
for the Blind renovations, school tutoring, etc.
Walk for Diabetes Fundraiser, Louisville, KY, 2000.
Part of group to Eastern Kentucky (Appalachia) to provide needed home repairs for elderly
residents, 2001.
Tutored grade K-12 inner city in Math, English, Spelling (Here’s Life Inner City), 2001-2002.
Taught English to Chinese Middle School Students in Hubei Province, China, Summer 2002.
Lead volunteer group to gut houses in 9th ward and other hard hit areas in New Orleans, 2006.
English tutoring for Burundi Refugees through Kentucky Refugee Services, 2007.
Susan R Komen Race for the Cure, 10K Run, 2012.
6.

TEACHING

PHPH 610, Data and Statistics Management for Public Health using SPSS, Co-Instructor, Spring
2013.
PHST 724, Advanced Clinical Trials, Co-Instructor and Teaching Assistant, Spring 2013.
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Graduate Level Course Lecture, Reliability Testing and Analysis, GE Appliances, Course
approved for graduate credit in Engineering by University of Louisville, (2000-2002).
One-week Reliability Analysis Course, Shanghai, China, and Seoul, Korea to GE Design
Engineers, Quality Engineers, and Sourcing Managers (August, 2001).
One-week Reliability Course to GE Supplier Engineers in Guangzhou, China (February, 2002).
Co-developed and taught Short Course in Logistic Regression (GE Appliances, 2001).
Developed and taught Accelerated Testing Short Course at GE Appliances (2000-2003).
Taught English to Chinese Middle School Students in Hubei Province, China (Summer 2002).
Monte Carlo Simulation short course instructor at GE Plastics (1998).
40 hour course (Statistical Process Control), Graco Children’s Products (1991-1996).
Short Course in Design of Experiments – Graco Children’s Products (1996).
Basic health course for West African Village (1982-1985) – focus on water usage and health.
7.

LANGUAGES

English (fluent), French (spoke daily for 2 ½ years), Chinese Mandarin (Advanced), Italian
(Intermediate), Birifor (West African Language – basic), Spanish (basic).
8.

STATISTICAL SOFTWARE PACKAGES/PROGRAMMING

R
SAS
Bioconductor
dChip
S-PLUS
SPSS
nQuery Advisor
East
ALTA
Process Model (Simulation)
Link Plus (Probability Matching)
GSEA/GSA (Pathway analysis software)
Genetic/SNP Analysis Software packages
8b.

Partek
East
NCSS/PASS
Xemacs
Ingenuity
Excel
StatXact
Weibull++
RG (Growth Models)
ProModel – (Simulation)
Minitab
Access
DAVID

TRAINING

Bayesian Methods in Pharmaceutical Development, ASA Webinar, Biopharmaceutical Section,
Instructors Karen Price, Mani Lakshminarayanan (November 2014)
Genomic Clinical Trials and Predictive Medicine, Instructor-Richard Simon, One day short
course at Joint Statistical Meeting, (August 2014).
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Partek software for NextGen sequencing- Alignment, QA/QC, Downstream Analysis, etc.
(February 2013).
National Institute of Environmental Health Sciences (NIEHS) SNPs Two-day Workshop,
1/11/2008 (Training in Genetic/SNP Analysis)
National Science Foundation (NSF) - Funded Short Course on Statistical Genetics and Statistical
Genomics (1 Week, UAB, July, 2008)
Joint Statistical Meeting (JSM) One-Day Short Course: Statistical Methods for Genetic Analysis,
Kenneth Lange (August 2007).
JSM One-Day Short Course: Probability Linkage (August 2007).
8c.

COMMITTEES

Software Committee- developed Access database to keep track of department software license
statistics by person, by contract, company, etc.
9.

CERTIFICATIONS

American Society for Quality (ASQ) Certified Reliability Engineer since 1992.
ASQ Certified Quality Engineer since 1991.
ASQ Certified Quality Auditor since 1992.
Certified Six Sigma Instructor (General Electric, 1998-2003).
Certified Six Sigma Leader (General Electric, 2000-2003).
Certified Statistical Process Control Instructor (Quality Institute ~1994).
GE Reliability Expert (1999-2003).
GE Certified Reliability Practitioner (2000).
Certified over 25 Reliability Practitioners (2000-2003).
10.

PROFESSIONAL SOCIETIES

American Statistical Association (Kentucky Chapter) since 1996.
11.

EDITORIAL BOARD, COUNCILS AND COMMITTEES – SERVICE.

Reviewer for Journal of Biometrics & Biostatistics, 2014 - present.
American Statistical Association (ASA), Vice Chair District 2, Region 1, Council of Chapters
Governing Board, 2012-2014.
American Statistical Association, Kentucky Chapter Judge, duPont Manual High School Regional
Science Fair, Louisville, KY, 2012.
American Statistical Association, Kentucky Chapter Representative, 2004- 2012.
American Statistical Association Judge, International Science and Engineering Fair, Louisville,
KY, 2002.
Chaired GE Appliances Reliability Practitioner (Survival Analysis) Best Practices monthly
conference meetings 2000-2003.
ASME (American Society for Mechanical Engineers) Student Chairman, Syracuse University,
1982.
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12.

AWARDS AND NAMED LECTURESHIPS

Magna Cum Laude, Syracuse University, 1982.
Outstanding Academic Achievement Award, Pennsylvania State University, 1998.
GE Call Center Simulation Award, 1998.
GE Instructor for Graduate Level Engineering Course Lecture in Reliability, 1999-2003.
GE Certified Six Sigma Trainer, 1997-2003.
GE Appliances Survival Analysis Expert, 2000-2003.
GE Certified Six Sigma Black Belt, 2000-2003.
GE Patent Award ($1,000) – Smoothing Algorithm for Dryer Sensor, 2001.
GE Patent Award ($1,000) - Design of Internet Based Supplier Reliability System, 2001.
ASA Judge, International Science and Engineering Fair, Louisville, Kentucky, 2002.
US Patent 6,675,129 - Internet Based Supplier Process Reliability System, 2004.
US Patent 7,013,578 - System and method for controlling a dryer appliance, 2006.
13.

POSTERS/PRESENTATIONS/ABSTRACTS

Classification of Clinical Outcomes Using High-Throughput Data, Alexander Cambon, Kathy B
Baumgartner, Guy N Brock, Nigel GF Cooper, Dongfeng Wu, Shesh N Rai; Joint Statistical
Meeting, Boston (August 2014).
An Evaluation of a Simon 2-Stage Phase II Clinical Trial Design Incorporating Continuous
Toxicity Monitoring, Herman Ray, D Kumar Srivastava, Alexander Cambon, Shesh N Rai
(2014).
Model Based Classifications of High-Throughput Data- Review, Design and Application to a
Cancer Clinical Study, Alexander Cambon, Shesh N Rai; Joint Statistical Meeting, Montreal
(July-August 2013).
A review of classification methods which could be used to identify a subset of patients in a
clinical study”, Alexander Cambon, Shesh N Rai; Joint Statistical Meeting, San Diego (JulyAugust 2012).
Invited Guest Lecturer for Graduate Course Seminar Series PHST 602. Presentation entitled
"Gene Set Analysis" (January 2009).
Presentation of statistical analysis of bioinformatics project: “Response of Oral Cavity Cells to
Cigarette Smoke Components”, Louisville, GEGIB-BBCB (February 2008).
Poster Presentation: “Using Link Plus for Probability Matching in Kentucky’s Newborn
Screening and Birth Defects Data”, Alexander Cambon, Sandy Fawbush, Charles Mundt, Joyce
Robl; Maternal Child Health Conference, Atlanta (December 2007).
Invited Guest Lecturer for Biostatistics Seminar (coordinated by Dr. Rempala) Presentation
entitled "Analysis of a Probe Level Linear Mixed Model for Oligonucleotide Arrays" (March
2007).
Contributed Presentation: “Analysis of a Probe Level Linear Mixed Model for Oligonucleotide
Arrays”, Alexander Cambon, Dr. Caryn Thompson, Dr. Brian Wattenberg, Joint Statistical
Meeting (August 2006).
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Poster Presentation: “Probe Level Patterns in Affymetrix Microarrays”, Alexander Cambon,
Abdelnaby Khalyfa, Caryn Thompson, Nigel Cooper, Kentucky KBRIN conference, LandBetween-the-Lakes (April 2006).
Poster Presentation: “Pathway Analysis and Gene Signal Identification of Microarray Data for
Apoptosis Induced Retinal Ganglion Cells”, Alexander Cambon, Abdelnaby Khalyfa, Caryn
Thompson, Nigel Cooper; CHI Pathway Analysis Conference, San Francisco (February 2006).
Invited Guest Lecturer for Graduate Course in Survival Analysis. Presentation entitled "Recurrent
Events Analysis" (November 2004).
An Application of Recurrent Events Analysis, Joint Statistical Meeting Proceedings, Toronto,
Canada (Summer 2004).
Invited Guest Lecturer for PHDA 602, University of Louisville; Survival Analysis Methods in
Industry (2003).
ASA/QPRC Northeast Meeting; “Using Monte Carlo simulation to Estimate an Optimum Ratio
of “Good” to “Bad” Parts in an Attribute Gage Study” (1998).
“An Application of Design Experiments in Design of Baby Swings”, American Society for
Quality, Reading, PA Chapter, ~1993.
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